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ABSTRACT: The importance of phosphonoamidate prodrugs (ProTides) of acyclic 
nucleoside phosphonate (ANPs) is highlighted by the approval of Tenofovir Alafenamide 
Fumarate for the treatment of HIV and HBV infections. In the present paper we are 
reporting an expedient, one-pot, two-steps synthesis of allyl phosphonoamidates and 
diamidates that offers a time saving strategy when compared to literature methods. The 
use of these substrates in the cross metathesis reactions with alkenyl functionalised 
thymine and uracil nucleobases is reported. ANPs prodrugs synthesized via this 
methodology were evaluated for their antiviral activities against DNA and RNA viruses. 
It is anticipated that the use of 5,6,7,8-tetrahydro-1-napthyl as aryloxy moiety is capable 
to confer antiviral activity among a series of otherwise inactive uracil ProTides. 
 
1 Introduction The ProTide approach, pioneered by Chris Mcguigan’s group[1, 2], is a powerful 
technology aimed to optimize intracellular drug delivery and circumvent metabolic 
bottlenecks in the activation of nucleoside-based antivirals and anticancer drugs. In the 
last years this technology has displayed a great deal of success in the antiviral field with 
two compounds in the market: the phosphoramidate Sofosbuvir [3, 4] (Sovaldi®) 
approved in 2013 against HCV infections and the phosphonamidate tenofovir 
alafenamide fumarate[5] (TAF, Vemlidy®) approved in 2015 for the treatment of HIV[6, 
7] and later in 2016 for HBV infections[8, 9] (Figure 1). 
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Figure 1. Structures of Sofosbuvir and TAF. 
 
Several other ProTides have entered in clinical trials while many others are in 
preclinical evaluation either as antiviral or anticancer drugs.[2, 10, 11] Given the 
tremendous importance of phosphor(n)oamidate prodrugs in the antiviral arena and 
beyond, after the approval of Sofosbuvir and TAF, the application of the ProTide 
technology has grown dramatically and it has started to show very promising results in 
other therapeutic area as well.[12-14] While there are several efficient procedures to 
synthesize phosphoroamidate nucleosides, the phosphonoamidate cognate class 
especially of acyclic nucleoside phosphonates (ANPs) lacks of such plethora of synthetic 
methodologies.[15] 
ANPs play a key role in the treatment of viral infections, and this class of compounds can 
be regarded as one of the most significant group of drugs in the antiviral field.[16, 17] 
Discovered almost 30 years ago, a great wealth of research has been dedicated to the 
development of efficient synthetic methodologies that resulted in a great variety of 
ANPs.[18-22] These new structures offer a potential for the discovery of more effective 
drugs against a variety of infectious diseases including antiparasitic,[23-29] 
antimicrobial,[30-33] and antitubercolous[34, 35] medicines. Among these synthetic 
strategies, quite recently, Agrofoglio’s group has elaborated a novel, efficient and 
straightforward synthesis of C5-alkenyl substituted ANPs via olefin cross-
metathesis.[36-42] Although structure-activity relationship (SAR) studies on acyclic 
nucleosides have not clarified their pharmacophore model, the introduction of a rigid 
structural element such as the double bond has proved to be extremely important for 
their antiviral activity.[43, 44] Precisely, the trans-alkene skeleton is able to mimic the 
three-dimensional geometry of the ribose ring maintaining also an electronic 
contribution similar to the one provided by the oxygen.[45] There are considerable 
evidences that the trans-alkenyl acyclic nucleotide motif has a strong affinity with 
recombinant human thymidylate kinase (hTMPK) active site, responsible for the 
nucleotide phosphorylation and consequently correlated to its antiviral 
activity.[41])nterestingly, Agrofoglio’s group employed the olefin cross-metathesis 
methodology also for the direct synthesis of a vast array of unsaturated ANPs analogues 
including bis-POM, bis-POC, and alkoxyesters prodrugs.[36, 38-41, 46, 47] Although 
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adopting a different procedure, our group extended the range of prodrugs of (E)-but-2-
enyl-pyrimidine, by synthesising their ProTide and bisamidate derivatives.[48] In this 
study we showed that the ProTide technology was able to broaden the spectrum of 
antiviral activity when compared to other phosphate prodrug approaches. However, we 
discovered that this methodology suffers from the limitation that only linear olefin must 
be employed, as with trisubstituted alkenyl derivatives we observed only formation of 
traces of the desired ProTides. This finding prompted us to investigate the possibility of 
using the cross-metathesis for the direct synthesis of unsaturated branched ANP 
phosphonoamidates. At the time we started this investigation, no application of such 
procedure for the synthesis of ProTides was yet reported. However, during the 
preparation of this manuscript, a paper reporting the use of the cross metathesis for the 
synthesis of ProTide derivatives of linear (E)-but-2-enyl nucleoside scaffold, was 
published.[49] The prodrugs described in this work belong to the same family of 
compounds previously reported by us,[48] and indeed their antiviral profile was in 
agreement with our published results. In the present article, we would like to report an 
effective and improved methodology for the synthesis of allyl phosphonoamidate and 
their further application in olefin cross-metathesis for the synthesis of ANP ProTides. 
We also anticipate that our two-steps, one-pot methodology can also be applied to the 
synthesis of symmetrical allyl phosphonodiamidates. Compared with the recently 
published procedure,[49] our synthetic strategy presents some advantages which we 
believe, merit consideration. 
2 Results and Discussion 
2.1 Chemistry 
Our research began with the synthesis of the aryloxy allylphosphonoamidate synthon 
3a, for which the only literature procedure available is a long and tedious multistep 
sequence.[50, 51] Based on our experience in the application of (oly’s one-pot 
procedure for the direct synthesis of phosphonodiamidates,[52] we envisaged that this 
protocol could be used to get access to the desired synthon starting from the 
commercially available dimethyl allylphosphonate 1 (Scheme 1). This methodology was 
already adapted in our laboratory for the synthesis of adefovir and tenofovir 
phosphonoamidate prodrugs[53] and more recently for the preparation of (E)-but-2-
enyl pyrimidine ProTides.[48] Briefly, commercial the dimethyl allylphosphonate 1 was 
converted into the corresponding silyl ester 2, by reaction with an excess of 
bromotrimethylsilane (5.0 equivalents). Due to the hydrolytically instability of this 
ester, 2 was not isolated but immediately dissolved in a mixture of pyridine/Et3N and 
treated with the L-alanine iso-propyl ester hydrochloride (1.0 equivalents), an excess of 
naphthol (6.0 equivalents), and a premade solution of PPh3 (6.0 equivalents) and 
aldrithiol-2 (6.0 equivalents) in pyridine. After 16 hours, the crude mixture did not show 
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the presence of either the desired product or phosphonodiamidate compound (which, 
based on our experience, is almost invariably formed). We attributed this lack of 
reactivity to the decomposition of the disilyl ester 2 caused by the release of 
hydrobromic acid, generated by the hydrolysis of the excess of TMSBr used. Pleasingly, 
when we attempted the reaction in the presence of 2,6-lutidine (4.0 equivalents) as acid 
scavenger, the formation of desired product 3a was observed (31P-NMR and LC-MS 
analysis of the crude mixture). 3a was isolated by flash chromatography in excellent 
yield (79%) (Table 1, Entry 1). Quite surprisingly, no evidence of side reactions[48] 
(bromination of the double bond and formation of the phosphonodiamidate) have been 
observed.  
 
 
Scheme 1. Synthesis of O-Aryl-(L-alanine-ester)-allylphosphonate. Reagents and 
conditions: i. TMSBr (5.0 equiv), 2,6-Lutidine (4.0 equiv), CH3CN, rt, 16 h; ii. Amino acid 
ester hydrochloride (1.0 equiv), aryl-alcohol (6.0 equiv), Et3N (15.0 equiv), aldrithiol-2 
(6.0 equiv), PPh3 ȋ͸.Ͳ equivȌ, pyridine, ͷͲ˚C, ͳ͸ h.  
Table 1. Substitution pattern and isolated yields of allyl phoshonamidates 3a-f. 
Entry Cpds Aryl Amino acid Ester Yielda 
1 3a 1-Naph L-Ala i-Pr 79% 
2 3b 1-Naph L-Ala Bz 78% 
3 3c Ph L-Ala i-Pr 65% 
4 3d Ph L-Ala Bz 42% 
5 3e TH-1-Naph L-Ala i-Pr 55% 
6 3f TH-1-Naph L-Ala Bz 55% 
a Yield are determined for isolated, purified compounds; see experimental part for 
details. 
With the above methodology, we prepared six different allyl phosphonate analogues 3a-
f in which a variety of aryloxy groups were introduced in combination with two different 
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amino acid esters (L-Alanine iso-propyl or benzyl esters). From Table 1 it can be 
appreciated that our method worked well with aryl alcohols with different steric 
requirements. In particular, we were able to prepare the allyl phosphonoamidates 
bearing the 5,6,7,8-tetrahydro-1-napthol 3e and 3f (Entries 5 and 6, Table 1), which 
have shown to impart remarkable antiviral activities in compounds of previous 
series,[48, 53]. 
This procedure is short and efficient, representing an improvement of the literature 
method, which accounts for a 29 % overall yield in four steps.[49] 
With these allyl phosphonoamidates in hand we began the synthesis of (E)-methylbut-2-
enyl pyrimidine 6 and 7, selected as the other partner for the cross-metathesis reaction. 
These nucleosides and their bis-POM prodrugs were originally prepared by Agrofoglio 
and colleagues,[38] which found the latest to have moderate activities against feline 
herpes virus (FHV) and feline corona virus (FCoV). Considering that ProTides of alkenyl pyrimidine with ǲlinearǳ ȋE)-but-2-enyl double bond have shown improved antiviral 
activities and a broad antiviral spectrum when compared to the corresponding bis-POM 
derivatives, we were now interested in investigating whether ProTide of branched 
alkenyl pyrimidine might have the same effect. We therefore synthesised a thymine and 
uracil derivative 6 and 7 as reported in Scheme 2. 
 
 
Scheme 2. Synthesis of N1-ʹ’-methylallylpyrimidine. Reagents and conditions: i. 3-
Bromo-2-methylpropene (2.0 equiv), BSA (2.5 equivalents), NaI (1.1 equiv), TMSCl (1 
equiv), CH3CN, reflux temperature, 16 h. 
With both alkenyl derivatives in hand we were in the position to investigate the cross-
metathesis conditions between the aryloxy allylphosphonoamidate synthon 3a and the 
olefin 6 as model reaction.  First we employed the same CM conditions developed and 
used by Agrofoglio for the synthesis of the corresponding bis-POM alkenyl 
derivatives[38]. As expected we obtained a mixture of E/Z isomers of which the desired 
compound E-8a was afforded in 24% yield (Entry 1, Table 2). Both E-8a and Z-8a 
isomers were isolated by preparative reverse phase-HPLC and their configurations were 
confirmed by NOESY experiments. The homodimer 9a was formed along with the E/Z 
derivatives. Any attempt to improve the reaction outcome using different catalysts 
(Hoveyda-Grubbs 2nd generation catalyst (A), Grubbs 2nd generation catalyst (B) and 
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Grubbs catalyst C859 (C)) failed providing 8a in similar or lower yield and almost 
identical E/Z ratio (Entries 2-3, Table 2). Since catalyst A resulted the best in terms of 
product/ homodimer ratio further screening was conducted keeping A as catalyst. 
Prolonged reaction time (Entry 4, Table 2) resulted in a slightly increased yield that 
however, was not further improved with addition of more catalyst (Entry 5, Table 2,). 
These conditions are different from those reported by Agrofoglio in his recent 
paper[49], where (E)-but-2-enyl pyrimidine ProTides were formed via cross metathesis 
only when water was used as solvent. 
 
 
Table 2. Screened conditions for CMa 
  
Entry cat E-8a/9 E-8a/Z-8a 8a(%) 
1b A 1 : 0.4 1 : 0.2 24% 
2b B 1 : 1.4 1 : 0.1 11% 
3b C 1 : 9 1 : 0.7 3% 
4c A 1 : 0.3 1 : 0.2 26% 
5c,d A 1 : 0.3 1 : 0.2 26% 
aReaction conditions: allyl phosphonoamidates 3a (1.0 equiv), olefin 6 (2.0 equiv) in 
CH2Cl2 at reflux temperature. Catalyst (5 mol%) added at t= 0, 2, 4 h. Ratio Het/Homo 
and E/Z determined by HPLC. bReactions sonicated for 24 h. cReactions sonicated for 36 
h. dfurther addition of the catalyst (5 mol%) after 24h. 
Using these conditions, we prepared different aryloxy phosphonoamidates of both 
thymine and uracil derivatives. The desired compounds E-8a-f and E-10a-f were 
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isolated in moderate yields (Scheme 3, Table 3). In few cases Z-isomers (Z-8a, Z-8e, Z-8f, 
Z-10e) were also isolated in 1 to 7% yield (Scheme 3, Table 3). 
 
 
Scheme 3. ProTide synthesis via cross-metathesis. Reagents and conditions: allyl 
phosphonoamidates 3a-f (1.0 equiv), olefin 6 or 7 (2.0 equiv) in CH2Cl2 at reflux 
temperature; Hoveyda-Grubbs 2nd generation catalyst (5 mol%) added after 0, 2 and 4 h; 
reactions sonicated for 24 h;  
Table 3. Substitution pattern and isolated yields of phosphoramidates E-8a-f and E-
10a-f 
 Cpds  R R1 R2 Yielda 
E-8a 1-Naph i-Pr CH3 36% 
E-8b 1-Naph Bz CH3 13% 
E-8c Ph i-Pr CH3 10% 
E-8d Ph Bz CH3 23% 
E-8e 
TH-1-
Naph 
i-Pr CH3 26% 
E-8f 
TH-1-
Naph 
Bz CH3 14% 
E-10a 1-Naph i-Pr H 14% 
E-10b 1-Naph Bz H 5% 
E-10c Ph i-Pr H 10% 
E-10d Ph Bz H 18% 
E-10e 
TH-1-
Naph 
i-Pr H 11% 
E-10f 
TH-1-
Naph 
Bz H 5% 
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ayields were determined for isolated, purified compounds; see experimental part for 
details. 
 
Pleased by the outcome of the above procedure, and to expand the versatility of this 
methodology, we decided to use the same reaction conditions to prepare the 
symmetrical phosphonodiamidate 12. Briefly, the desired bis-amidate intermediate 11 
was obtained in 52% yield by treating the allyl phosphonate 1 with an excess of TMSBr 
(in presence of 4.0 equivalents of lutidine) and the resulting silyl diester reacted with an 
excess (5.0 equivalents) of L-alanine iso-propyl hydrochloride (Scheme 4). Compound 
11 was then subjected to olefin cross-metathesis reaction with compound 7 under the 
conditions reported in Scheme 4. Phosphonodiamidate 12 was obtained as a mixture of 
the E and Z isomers. The E-isomer was isolated in 2% yield, after purification by 
preparative reverse phase-HPLC. 
  
Scheme 4. Synthesis of symmetrical allyl phosphonodiamidate 12. Reagents and 
conditions: i. TMSBr (5.0 equiv), 2,6-Lutidine (4.0 equiv), CH3CN, rt, 16 h; ii. benzyloxy-L-
Alanine hydrochloride (5.0 equiv), Et3N (15.0 equiv), Aldrithiol-2 (6.0 equivalents), PPh3 ȋ͸.Ͳ equivȌ, pyridine, ͷͲ˚C, ͳ͸ h; iii. N1-ʹ’-methylallyl-uracil 7 (2 equiv), Hoveyda-Grubbs 
2nd generation catalyst (15 mol%), CH2Cl2, sonicated for 24 h, at reflux temperature. 
 
Since ruthenium catalyst was used during the synthesis, we were interested in 
measuring its residual amount in the final sample. ICP-MS experiment on compound E-
10e showed ruthenium content of 0.116 mg/g. Further purification [54] will have to be 
considered if this methodology will be used for preparing compounds progressing to 
preclinical and clinical evaluation in order to comply the FDA recommended limits for 
residual metal catalyst in a drug. [55] 
2.2 Antiviral activity and Serum stability 
All the ProTide derivatives synthesised were evaluated against a panel of DNA and RNA 
viruses as previously described.[48] None of the compounds were active against herpes 
simplex virus-1 (KOS) (HVS-1), herpes simplex virus-2 (G) (HVS-2), thymidine kinase 
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deficient herpes simplex virus-1 (KOS Acyclovir-resistant strain) (TK- HSV-1), vaccinia 
virus (VV), adenovirus-2 (AV-2), human coronavirus (HCoV-229E) in HEL cells, 
parainfluenza-3 virus (HPIV-3), reovirus-1 (REO-1), vesicular stomatitis virus (VSV), 
respiratory syncytial virus (RSV) in HeLa cells, influenza A/H1N1, influenza A/H3N2 
and influenza B in MDCK cells. 
As shown in table 4, thymine derivatives E-8a-f showed weak antiviral activity against 
varicella-zoster virus (VZV TK+ and TK-) and human cytomegalovirus (HCMV AD-169 
strain and Davis strain) with EC50 ranging from 20 to 76 M, whereas uracil derivatives 
E-10a-c were mostly inactive against these viruses with the exception of E-10a (EC50 = 
20M VZV TK+) and E-10b (EC50 = 58M VZV TK-). Interestingly uracil derivatives E-
10e-f, bearing the 5,6,7,8-tetrahydro-1-napthol as aryl moiety, resulted slightly active 
against VZV both TK+ and TK- strains, confirming once again the biological potential of 
this promoiety. No specific information about the 5,6,7,8-tetrahydronaphtol LD50 is 
reported in the literature as for phenol and 1-napthol. However, in previous studies [48, 
53] we have shown that in an in vitro assay the CC50 values of ANP ProTides bearing the 
5,6,7,8 tehydro-1-napthyl moiety have a comparable CC50 values to those bearing phenol 
and 1-napthol. This is also observed in the presented studies. Remarkably, all the Z 
isomers isolated (Z-8a,e,f and Z-10e) showed to some extent antiviral activity against 
both AD-169 and Davis HCMV strains. Furthermore, compound Z-8e was found weakly 
active against Sindbis Virus (SINV), coxsackie virus B4, Punta Toro virus (PTV) and 
yellow fever virus (YFV) in Vero cells with EC50 values in the range of 20-58 µM.  
None of the compounds showed significant cytotoxicity. Being able to inhibit VZV, 
ProTides of allylphosphonate pyrimidine showed a broader antiviral activity than the 
corresponding bis-POM prodrugs, previously reported by Agrofoglio.[41] On the 
contrary linear alkenyl derivatives showing higher EC50 against VZV perform better than 
those branched, suggesting that a more substituted double bond is detrimental for the 
antiviral activity. 
Table 4. Antiviral activity of alkenyl ANP ProTides 
Cpds 
EC50(HEL cells)(µM) MCC (HEL cells) 
(µM) 
EC50(Vero cells)(µM) MCC (Vero 
cells)(µM) VZV HCMV SINV Coxsackie 
Virus B4 
PTV YFV 
TK+ TK- AD-169 Davis 
E-8a 44.72 >100 >100 >100 >100 >100 >100 >100 >100 ≥20 
E-8b 34.2 55.27 >100 >100 >100 >100 >100 >100 >100 >100 
E-8c 76.47 >100 >100 >100 >100 >100 >100 >100 >100 ≥20 
E-8d 55.7 46.66 >100 >100 >100 >100 >100 >100 >100 >100 
E-8e 58.48 53.48 >100 >20 >100 >100 >100 >100 >100 ≥20 
E-8f 50.17 47.19 >100 >100 >100 >100 >100 >100 >100 ≥ͳͲ0 
E-10a 20 >100 >100 >100 >100 >100 >100 >100 >100 >100 
E-10b 100 58.48 >100 >100 >100 >100 >100 >100 >100 >100 
E-10c >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
E-10d >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
E-10e 29.91 71.52 >100 >100 >100 >100 >100 >100 >100 >100 
E-10f 55.7 52.53 >100 >100 >100 >100 >100 >100 >100 ≥100 
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Z-8a 39.86 41.57 >20 44.72 100 >100 >100 >100 >100 ≥20 
Z-8e >20 >20 44.72 >20 100 45 58 45 58 >100 
Z-8f 17.03 65.1 76.47 76.47 >100 >100 >100 >100 >100 ≥20 
Z-10e 58.48 100 >20 54.69 100 >100 >100 >100 >100 >100 
Acyclovir 3.55 14.87 - - >440 - - - - - 
Brivudin 0.012 0.57 - - >300 - - - - - 
Ganciclovir - - 11.43 2.29 - - - - - - 
Cidofovir - - 1.24 0.76 -   - - - 
DS-10.000 - - - - - 20 7.6 7.6 34 >100 
Ribavirin - - - - - >250 >250 126 >250 >250 
Mycophenolic 
acid 
- - - - - 4 >100 6.1 4 >100 
EC50: 50% effective concentration or concentration required inhibiting viral induced cytopathic effect (HCMV, SINV, 
coxsackie virus B4, PTV and YFV) or plaque formation (VZV) by 50%. 
MCC: minimal cytotoxic concentration that causes a microscopically alteration of cell morphology. 
 
The metabolic activation of phosphonoamidates follows the same two-enzymatic steps 
involved in the activation of the phosphoroamidates.[11] Although the use of 5,6,7,8-
tetrahydro-1-naphthol as aryloxy group in the ProTides is quite recent we have shown 
its metabolic activation by carboxypeptidase Y in previous studies.[53] To prove the 
stability of this class of compound we have performed stability assays of compound E-
8e, in rat and human sera, which indicate a suitable pharmacokinetic profile of the 
tested phosphonoamidate with a half-life higher than 12 hours (Fig.2). 
 
Figure 2. Stability assay of E-8e in Human Serum at 37˚C monitored by 31P NMR (202 
MHz, DMSO-d6/H2O). 
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3 Conclusion 
In conclusion, we have successfully reported the one pot-two steps synthesis of a family 
of allyl phosphonoamidates. Our methodology is an important improvement of a 
recently reported strategy[49] that allows the synthesis of these substrate in a shorter 
synthetic sequence and with an overall higher yield. We also extended this protocol to 
the synthesis of hitherto unknown allylphosphonoamidate. We also proved that both 
synthons are capable to undergo alkene cross-metathesis with alkenyl functionalized 
uracil and thymine nucleobases although the yields need to be further optimized, 
especially in the case of phosphonodiamidates. These phosphonoamidate prodrugs were 
evaluated for their biological activity against a panel of DNA and RNA viruses. None of 
the compounds prepared, showed significant cytotoxicity. ProTides of allylphosphonate 
pyrimidine showed a broader antiviral activity than the corresponding bis-POM 
prodrugs against VZV infected cells. We have also demonstrated, once again, that the 
introduction of 5,6,7,8-tetrahydro-1-naphthyl moiety into the ProTide scaffold is 
capable to increase the antiviral activity of the prodrug. Finally, not only the E-isomers 
showed some biological activity, but also all the Z isomers isolated (Z-8a,e,f and Z-10e) 
showed to some extent antiviral activity against both AD-169 and Davis HCMV strains. 
Further studies directed to the optimization of the cross metathesis procedure 
especially for the allylphosphonoamidate, are currently in progress in our laboratory. 
4 Experimental section 
4.1 Chemistry 
All solvents used were anhydrous and used as supplied by Sigma-Aldrich. All 
commercially available reagents were supplied by either Sigma-Aldrich or Fisher and 
used without further purification. All nucleosides and solid reagents were dried for 
several hours under high vacuum prior to use. For analytical thin-layer chromatography 
(TLC), precoated aluminium-backed plates (60 F-54, 0.2 mm thickness; supplied by E. 
Merck AG, Darmstadt, Germany) were used and developed by an ascending elution 
method. For preparative thin-layer chromatography (prep TLC), preparative TLC plates 
(20 cm x 20 cm, 500-ʹͲͲͲ ɊmȌ were purchased from Merck. After solvent evaporation, 
compounds were detected by quenching of the fluorescence, at 254 nm upon irradiation 
with a UV lamp. Column chromatography purifications were carried out by means of 
automatic Biotage Isolera One. Fractions containing the product were identified by TLC 
and pooled, and the solvent was removed in vacuo. 1H, 31P and 13C NMR spectra were 
recorded in a Bruker Avance 500 spectrometer at 500 MHz, 202 MHz and 125 MHz 
respectively and auto-calibrated to the deuterated solvent reference peak in case of 1H 
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and 13C NMR and 85% H3PO4 for 31P NMR experiments. All 31P and 13C NMR spectra were 
proton-decoupled. Chemical shifts are given in parts per million (ppm) and coupling 
constants (J) are measured in Hertz (Hz). The following abbreviations are used in the 
assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), 
bs (broad singlet), dd (doublet of doublet), ddd (doublet of doublet of doublet), dt 
(doublet of triplet). The assignment of the signals in 1H NMR and 13C NMR was done 
based on the analysis of coupling constants and additional two-dimensional 
experiments (COSY, HSQC). Analytical High-Performance Liquid Chromatography 
(HPLC) analysis was performed using both Spectra System SCM (with X-select-C18, 5 
mm, 4.8 x 150 mm column) and Varian Prostar system (LCWorkstation- Varian Prostar 
335 LC detector). Preparative HPLC was performed with Varian Prostar (with pursuit 
XRs C18 150 x 21.2 mm column). Low and high-resolution mass spectrometry was 
performed on a Bruker Daltonics MicroTof-LC system (atmospheric pressure ionization, 
electron spray mass spectroscopy) in positive mode.  
The ≥ 9ϱ% purity of the fiŶal ĐoŵpouŶds (E-8a-f, E-10a-f, Z-8a,e,f and Z-10e) was confirmed 
using HPLC analysis. 
4.1.1 General procedure A for the preparation of O-Aryl-(L-Alanine-ester)-
allylphosphonate (3a-f). 
In a round bottom flask, under an argon atmosphere, 2,6-Lutidine (4 eq) and 
trimethylsilyl bromide (TMSBr, 5 eq) were added to a solution of dimethyl 
allylphosphonate (1 eq) in anhydrous acetonitrile (8 ml / mmol of allylphosphonate). 
The mixture was stirred 16 h at room temperature and then the volatiles evaporated 
without any contact with air. Then the flask was charged with dry aminoacid ester 
hydrochloride (1 eq), dry aryl-alcohol (6 eq), dry triethylamine (15 eq) and dry pyridine ȋ͵ ml / mmol of allylphosphonateȌ and heated to ͷͲ˚C to obtain a homogenous solution. 
To this mixture was then added a solution of Aldrithiol-2 (6 eq) and triphenylphosphine 
(6 eq) in dry pyridine (3 ml / mmol of allylphosphonate) under argon atmosphere. The resulting mixture was stirred at ͷͲ˚C for ͳ͸ h. After evaporating all the volatiles, the 
residue was purified by Biotage Isolera One. 
4.1.1.1 O-(1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate (3a) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry isopropyloxy-L-Alanine hydrochloride (558 
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mg, 3.33 mmol), dry 1-Naphthol (2.88 g, 19.98 mmol), dry triethylamine (6.9 ml, 49.96 
mmol) in dry pyridine (10 ml) and a solution of Aldrithiol-2 (4.40 g, 19.98 mmol) and 
triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 ml). After evaporation, the 
mixture was purified by Biotage Isolera One (100 g SNAP cartridge ULTRA, 100 ml/min, 
gradient eluent system EtOAc/Hexane 10% 1CV, 10-100% 12CV, 100% 2CV), to afford 
the title compound as a yellow oil (940 mg, 79%). Rf = 0.58 (EtOAc/Hexane - 4:6). 31P 
NMR (202 MHz, CD3OD) δP: 30.01, 29.43. 1H NMR (500 MHz, CD3OD) δH: 8.19 (d, J = 
7.2 Hz, 1H, ArH), 7.89 (d, J = 7.9 Hz 1H, ArH), 7.71-7.69 (m, 1H, ArH), 7.58-7.40 (m, 4H, 
ArH), 6.07-5.91 (m, 1H, CH=), 5.38-5.28 (m, 2H, CH2=), 5.95-4.82 (m, 1H, CH(CH3)2), 3.99-
3.97 (m, 1H, CHCH3 L-Ala), 3.03-2.93 (m, 2H, CH2P), 1.25 (d, J = 7.8 Hz, 1.5H, CHCH3 L-
Ala), 1.21-1.10 (m, 7.5H, CHCH3 L-Ala, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.5 
(d, 3JC-P = 4.2 Hz, C=O, ester), 173.1 (d, 3JC-P = 4.2 Hz, C=O, ester), 146.4 (d, 2JC-P = 8.5 Hz, C-
O, Ph), 146.3 (d, 2JC-P = 8.5 Hz, C-O, Ph), 134.9 (C-Ar), 127.4 (2JC-P = 9.3 Hz, CH=), 123.3 
(2JC-P = 10.9 Hz, CH=), 126.9 (d, 3JC-P = 5.6 Hz C-Ar), 126.8 (d, 3JC-P = 4.9 Hz C-Ar), 126.3 
(CH-Ar), 125.95 (CH-Ar), 125.90 (CH-Ar), 125.1 (CH-Ar), 125.0 (CH-Ar), 124.3 (CH-Ar), 
124.2 (CH-Ar), 121.6 (CH-Ar), 121.4 (CH-Ar), 119.7 (d, 3JC-P = 14.2 Hz CH2=), 119.6 (d, 3JC-P 
= 13.8 Hz CH2=), 115.4 (d, 3JC-P = 4.1 Hz CH-Ar), 115.2 (d, 3JC-P = 3.4 Hz CH-Ar), 68.6 
(CH(CH3)2), 68.5 (CH(CH3)2), 49.6 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 33.7 (d, 1JC-P = 
129.0 Hz CH2P), 33.5 (d, 1JC-P = 129.6 Hz CH2P), 20.5 (CH(CH3)2), 20.4 (CH(CH3)2), 20.3 
(CH(CH3)2), 19.7 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala). 
 
4.1.1.2 O-(1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate (3b) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry benzyloxy-L-Alanine hydrochloride (718 mg, 
3.33 mmol), dry 1-Naphthol (2.88 g, 19.98 mmol), dry triethylamine (6.9 ml, 49.96 
mmol) in dry pyridine (10 ml) and a solution of Aldrithiol-2 (4.40 g, 19.98 mmol) and 
triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 ml). After evaporation, the 
mixture was purified by Biotage Isolera One (100 g SNAP cartridge ULTRA, 100 ml/min, 
gradient eluent system EtOAc/Hexane 10% 1CV, 10-100% 12CV, 100% 2CV), to afford 
the title compound as a yellow oil (1.1 g, 78%). Rf = 0.58 (EtOAc/Hexane - 4:6). 31P NMR 
(202 MHz, CD3OD) δP: 30.09, 29.48. 1H NMR (500 MHz, CD3OD) δH: 8.17 (s, 1H, ArH), 
7.86 (s, 1H, ArH), 7.69-7.65 (m, 1H, ArH), 7.52-7.22 (m, 9H, ArH), 5.99-5.89 (m, 1H, CH=), 
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5.30-5.24 (m, 2H, CH2=), 5.09, 5.03 (ABq, JAB = 12.1 Hz, 1H, CH2Ph), 4.97, 4.93 (ABq, JAB = 
12.1 Hz, 1H, CH2Ph), 4.09-4.07 (m, 1H, CHCH3 L-Ala), 2.95-2.91 (m, 2H, CH2P), 1.26 (d, J = 
6.8 Hz, 1.5H, CHCH3 L-Ala), 1.16 (d, J = 6.8 Hz, 1.5H, CHCH3 L-Ala). 13C NMR (125 MHz, 
CD3OD) δC: 173.7 (d, 3JC-P = 3.9 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.0 Hz, C=O, ester), 146.4 
(d, 2JC-P = 9.7 Hz, C-O, Ph), 146.3 (d, 2JC-P = 10.0 Hz, C-O, Ph), 135.8 (C-Ar), 135.7 (C-Ar), 
134.9 (C-Ar), 128.17 (CH-Ar), 128.12 (CH-Ar), 127.9 (CH-Ar), 127.8 (CH-Ar), 127.48 (CH-
Ar), 127.42 (CH-Ar), 127.3 (2JC-P = 11.3 Hz, CH=), 127.2 (2JC-P = 11.0 Hz, CH=), 126.8 (d, 3JC-
P = 5.0 Hz C-Ar), 126.7 (d, 3JC-P = 5.3 Hz C-Ar), 126.3 (CH-Ar), 125.98 (CH-Ar), 125.93 (CH-
Ar), 125.18 (CH-Ar), 125.10 (CH-Ar), 124.3 (CH-Ar), 124.2 (CH-Ar), 121.6 (CH-Ar), 121.4 
(CH-Ar), 119.7 (d, 3JC-P = 15.2 Hz CH2=), 119.6 (d, 3JC-P = 14.9 Hz CH2=), 115.4 (d, 3JC-P = 3.9 
Hz CH-Ar), 115.2 (d, 3JC-P = 3.9 Hz CH-Ar), 66.5 (CH2Ph), 66.3 (CH2Ph), 49.6 (CHCH3 L-Ala), 
49.4 (CHCH3 L-Ala), 33.7 (d, 1JC-P = 129.2 Hz CH2P), 33.5 (d, 1JC-P = 129.7 Hz CH2P), 19.6 (d, 
3JC-P = 5.3 Hz, CHCH3 L-Ala), 19.0 (d, 3JC-P = 5.8 Hz, CHCH3 L-Ala). 
 
4.1.1.3 O-phenyl-(isopropyloxy-L-Alanine)-allylphosphonate (3c) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry isopropyloxy-L-Alanine hydrochloride (558.3 
mg, 3.33 mmol), dry Phenol (1.88 g, 19.98 mmol), dry triethylamine (6.9 ml, 49.96 
mmol) in dry pyridine (10 ml) and a solution of Aldrithiol-2 (4.40 g, 19.98 mmol) and 
triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 ml). After evaporation, the 
mixture was purified by Biotage Isolera One (100 g SNAP cartridge ULTRA, 100 ml/min, 
gradient eluent system EtOAc/Hexane 10% 1CV, 10-100% 12CV, 100% 2CV), to afford 
the title compound as a yellow oil (670 mg, 65%). Rf = 0.37 (EtOAc/Hexane - 6:4). 31P 
NMR (202 MHz, CDCl3) δP: 26.77, 26.35. 1H NMR (500 MHz, CDCl3) δH: 7.32-7.28 (m, 
2H, ArH), 7.22-7.20 (m, 2H, ArH), 7.14-7.13 (m, 1H, ArH), 5.95-5.82 (m, 1H, CH=), 5.32-
5.25 (m, 2H, CH2=), 5.00-4.94 (m, 1H, CH(CH3)2), 4.14-3.96 (m, 1H, CHCH3 L-Ala), 3.51 
(dd, 2JH-P, 3JNH,CH = 10.3 Hz, 0.5H, NH L-Ala), 3.41 (dd, 2JH-P, 3JNH,CH = 10.7 Hz, 0.5H, NH L-
Ala), 2.81-2.72 (m, 2H, CH2P), 1.29 (d, J = 7.2 Hz, 1.5H, CHCH3 L-Ala), 1.23-1.20 (m, 7.5H, 
CHCH3 L-Ala, CH(CH3)2). 13C NMR (125 MHz, CDCl3) δC: 173.5 (d, 3JC-P = 4.7 Hz, C=O, 
ester), 173.1 (d, 3JC-P = 4.7 Hz, C=O, ester), 150.6 (d, 2JC-P = 9.1 Hz, C-O, Ph), 150.5 (d, 2JC-P = 
9.4 Hz, C-O, Ph), 129.4 (CH-Ar), 129.3 (CH-Ar), 127.5 (2JC-P = 11.3 Hz, CH=), 127.4 (2JC-P = 
11.3 Hz, CH=), 124.6 (CH-Ar), 124.5 (CH-Ar), 120.8 (d, 3JC-P = 4.0 Hz CH-Ar), 120.6 (d, 3JC-P 
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= 4.0 Hz CH-Ar), 119.6 (d, 3JC-P = 14.6 Hz CH2=), 119.6 (d, 3JC-P = 14.6 Hz CH2=), 68.59 
(CH(CH3)2), 68.57 (CH(CH3)2), 49.6 (CHCH3 L-Ala), 49.7 (CHCH3 L-Ala), 33.8 (d, 1JC-P = 
129.3 Hz CH2P), 33.6 (d, 1JC-P = 129.7 Hz CH2P), 20.86 (CH(CH3)2), 20.82 (CH(CH3)2), 20.81 
(CH(CH3)2), 20.75 (CH(CH3)2), 20.0 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 19.5 (d, 3JC-P = 5.1 Hz, 
CHCH3 L-Ala). 
 
4.1.1.4 O-phenyl-(benzyloxy-L-Alanine)-allylphosphonate (3d) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry benzyloxy-L-Alanine hydrochloride (718 mg, 
3.33 mmol), dry Phenol (1.88 g, 19.98 mmol), dry triethylamine (6.9 ml, 49.96 mmol) in 
dry pyridine (10 ml) and a solution of Aldrithiol-2 (4.40 g, 19.98 mmol) and 
triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 ml). After evaporation, the 
mixture was purified by Biotage Isolera One (100 g SNAP cartridge ULTRA, 100 ml/min, 
gradient eluent system EtOAc/Hexane 10% 1CV, 10-100% 12CV, 100% 2CV), to afford 
the title compound as a yellow oil (500 mg, 42%). Rf = 0.22 (EtOAc/Hexane - 4:6). 31P 
NMR (202 MHz, CD3OD) δP: 29.64, 28.99. 1H NMR (500 MHz, CD3OD) δH: 7.35-7.28 (m, 
7H, ArH), 7.22-7.14 (m, 3H, ArH), 5.91-5.81 (m, 1H, CH=), 5.27-5.18 (m, 2H, CH2=), 5.14, 
5.12 (ABq, JAB = 12.5 Hz, 1H, CH2Ph), 5.06 (s app, 1H, CH2Ph), 4.10-4.01 (m, 1H, CHCH3 L-
Ala), 2.82-2.75 (m, 2H, CH2P), 1.31 (d, J = 7.2 Hz, 1.5H, CHCH3 L-Ala), 1.22 (d, J = 7.5 Hz, 
1.5H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 172.3 (d, 3JC-P = 4.1 Hz, C=O, ester), 
171.9 (d, 3JC-P = 3.9 Hz, C=O, ester), 149.0 (d, 2JC-P = 9.5 Hz, C-O, Ph), 148.9 (d, 2JC-P = 9.5 Hz, 
C-O, Ph), 134.37 (C-Ar), 134.34 (C-Ar), 127.84 (CH-Ar), 127.81 (CH-Ar), 126.75 (CH-Ar), 
126.73 (CH-Ar), 126.5 (CH-Ar), 126.49 (CH-Ar), 126.46 (CH-Ar), 125.8 (2JC-P = 10.1 Hz, 
CH=), 125.7 (2JC-P = 10.1 Hz, CH=), 123.1 (CH-Ar), 123.0 (CH-Ar), 119.2 (d, 3JC-P = 4.3 Hz 
CH-Ar), 119.0 (d, 3JC-P = 4.3 Hz CH-Ar), 118.2 (d, 3JC-P = 14.5 Hz CH2=), 118.0 (d, 3JC-P = 14.6 
Hz CH2=), 65.0 (CH2Ph), 64.9 (CH2Ph), 48.09 (CHCH3 L-Ala), 47.9 (CHCH3 L-Ala), 32.1 (d, 
1JC-P = 129.7 Hz CH2P), 31.9 (d, 1JC-P = 129.7 Hz CH2P), 18.2 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 
17.7 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala). 
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4.1.1.5 O-(5,6,7,8-tetrahydro-1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate 
(3e) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry isopropyloxy-L-Alanine hydrochloride (558 
mg, 3.33 mmol), dry 5,6,7,8-tetrahydro-1-naphthol (2.96 g, 19.98 mmol), dry 
triethylamine (6.9 ml, 49.96 mmol) in dry pyridine (10 ml) and a solution of Aldrithiol-2 
(4.40 g, 19.98 mmol) and triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 
ml). After evaporation, the mixture was purified by Biotage Isolera One (100 g SNAP 
cartridge ULTRA, 100 ml/min, gradient eluent system EtOAc/Hexane 10% 1CV, 10-
100% 12CV, 100% 2CV), to afford the title compound as a yellow foamy solid (750 mg, 
55%). Rf = 0.51 (EtOAc/Hexane - 4:6). 31P NMR (202 MHz, CD3OD) δP: 29.04, 28.43. 1H 
NMR (500 MHz, CD3OD) δH: 7.17-7.12 (m, 1H, ArH), 7.05-7.00 (m, 1H, ArH), 6.89-6.87 
(m, 1H, ArH), 5.99-5.85 (m, 1H, CH=), 5.32-5.24 (m, 2H, CH2=), 5.01-4.88 (m, 1H, 
CH(CH3)2), 3.98-3.89 (m, 1H, CHCH3 L-Ala), 2.85 (dt, 2JH-P = 2JH-H = 20.0 Hz, 3JH-H = 7.1 Hz, 
2H, CH2P), 2.77-2.74 (m, 4H, ArH), 1.80-1.79 (m, 4H, ArH), 1.30 (d, J = 7.1 Hz, 1.5H, 
CHCH3 L-Ala), 1.25-1.23 (m, 4.5H, CHCH3 L-Ala, CH(CH3)2), 1.19 (d, J = 6.05 Hz, 3H, 
CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.6 (d, 3JC-P = 4.0 Hz, C=O, ester), 173.2 (d, 
3JC-P = 4.0 Hz, C=O, ester), 148.7 (d, 2JC-P = 10.2 Hz, C-O, Ph), 148.6 (d, 2JC-P = 10.6 Hz, C-O, 
Ph), 139.1 (C-Ar), 131.3 (CH-Ar), 131.2 (CH-Ar), 128.6 (d, 3JC-P = 7.0 Hz C-Ar), 128.5 (d, 
3JC-P = 7.5 Hz C-Ar), 127.5 (2JC-P = 11.0 Hz, CH=), 127.4 (2JC-P = 11.0 Hz, CH=), 125.3 (CH-
Ar), 125.1 (CH-Ar), 119.4 (d, 3JC-P = 14.6 Hz CH2=), 119.3 (d, 3JC-P = 14.6 Hz CH2=), 116.9 
(d, 3JC-P = 3.1 Hz CH-Ar), 116.8 (d, 3JC-P = 3.5 Hz CH-Ar), 68.6 (CH(CH3)2), 68.5 (CH(CH3)2), 
49.7 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 33.8 (d, 1JC-P = 129.5 Hz CH2P), 33.6 (d, 1JC-P = 
130.1 Hz CH2P), 29.1 (CH2-Ar), 23.3 (CH2-Ar), 22.48 (CH2-Ar), 22.46 (CH2-Ar), 22.41 (CH2-
Ar), 20.59 (CH(CH3)2), 20.56 (CH(CH3)2), 20.54 (CH(CH3)2), 20.4 (CH(CH3)2), 19.9 (d, 3JC-P 
= 4.9 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala). 
 
4.1.1.6 O-(5,6,7,8-tetrahydro-1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate (3f) 
Prepared according to the standard procedure A for the synthesis of 
allylphosphonoamidate using dimethyl allylphosphonate (500 mg, 3.33 mmol), 2,6-
Lutidine (1.55 ml, 13.32 mmol), TMSBr (2.20 ml, 16.65 mmol) in anhydrous acetonitrile 
(25 ml). For the second step we used dry benzyloxy-L-Alanine hydrochloride (718 mg, 
3.33 mmol), dry 5,6,7,8-tetrahydro-1-naphthol (2.96 g, 19.98 mmol), dry triethylamine 
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(6.9 ml, 49.96 mmol) in dry pyridine (10 ml) and a solution of Aldrithiol-2 (4.40 g, 19.98 
mmol) and triphenylphosphine (5.24 g, 19.98 mmol) in dry pyridine (10 ml). After 
evaporation, the mixture was purified by Biotage Isolera One (100 g SNAP cartridge 
ULTRA, 100 ml/min, gradient eluent system EtOAc/Hexane 10% 1CV, 10-100% 12CV, 
100% 2CV), to afford the title compound as a yellow foamy solid (750 mg, 55%). Rf = 
0.51 (EtOAc/Hexane - 4:6). 31P NMR (202 MHz, CD3OD) δP: 28.81, 28.20. 1H NMR (500 
MHz, CD3OD) δH: 7.35-7.31 (m, 5H, ArH), 7.17-7.14 (m, 1H, ArH), 7.06-7.94 (m, 1H, 
ArH), 6.87-6.83 (m, 1H, ArH), 5.94-5.82 (m, 1H, CH=), 5.27-5.20 (m, 2H, CH2=), 5.13, 5.10 
(ABq, JAB = 12.2 Hz, 1H, CH2Ph), 5.04 (AB app t, JAB = 12.8 Hz, 1H, CH2Ph), 4.12-4.01 (m, 
1H, CHCH3 L-Ala), 2.86-2.77 (m, 2H, CH2P), 2.72-2.67 (m, 4H, ArH), 1.79-1.71 (m, 4H, 
ArH), 1.32 (d, J = 7.1 Hz, 1.5H, CHCH3 L-Ala), 1.26 (d, J = 7.1 Hz, 1.5H, CHCH3 L-Ala). 13C 
NMR (125 MHz, CD3OD) δC: 173.8 (d, 3JC-P = 3.7 Hz, C=O, ester), 173.4 (d, 3JC-P = 4.1 Hz, 
C=O, ester), 148.8 (d, 2JC-P = 9.7 Hz, C-O, Ph), 148.7 (d, 2JC-P = 9.4 Hz, C-O, Ph), 139.13 (C-
Ar), 139.11(C-Ar), 135.88 (C-Ar), 135.84 (C-Ar), 128.6 (d, 3JC-P = 5.5 Hz C-Ar), 128.5 (d, 
3JC-P = 5.8 Hz C-Ar), 128.23 (CH-Ar), 128.20 (CH-Ar), 127.99 (CH-Ar), 127.94 (CH-Ar), 
127.87 (CH-Ar), 127.5 (2JC-P = 11.3 Hz, CH=), 127.4 (2JC-P = 11.0 Hz, CH=), 125.4 (CH-Ar), 
125.3 (CH-Ar), 125.17 (CH-Ar), 125.13 (CH-Ar), 119.5 (d, 3JC-P = 14.6 Hz CH2=), 119.4 (d, 
3JC-P = 14.8 Hz CH2=), 117.0 (d, 3JC-P = 3.4 Hz CH-Ar), 116.9 (d, 3JC-P = 3.1 Hz CH-Ar), 66.5 
(CH2Ph), 66.4 (CH2Ph), 49.7 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 33.8 (d, 1JC-P = 129.4 Hz 
CH2P), 33.7 (d, 1JC-P = 130.2 Hz CH2P), 29.18 (CH2-Ar), 23.38 (CH2-Ar), 22.5 (CH2-Ar), 
22.48 (CH2-Ar), 22.43 (CH2-Ar), 19.8 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.3 Hz, 
CHCH3 L-Ala). 
 
4.1.2 General procedure B for the preparation of N1-2’-methylallylpyrimidine (6, 7) 
In a round bottom flask, under an argon atmosphere, to a solution of the nucleobase (1 
eq) in anhydrous acetonitrile (2 ml / mmol of nucleobase) was added BSA (2.5 eq). The 
mixture was refluxed until clear solution was observed (usually 5 min). 3-bromo-2-
methylpropene (2.0 eq), NaI (1.1 eq) and TMSCl (1 eq) were then added to the reaction 
mixture. The solution was refluxed 16 h and then evaporated under reduced pressure. 
The residue was dissolved in EtOAc, washed with NaHCO3 (aqueous saturated solution), 
Na2SO4 (aqueous saturated solution), H2O, brine and dried over MgSO4. The resulting 
mixture was evaporated and the residue was purified by Biotage Isolera One. 
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4.1.2.1 N1-2’-methylallyl-thymine (6) 
Prepared according to the standard procedure B for the synthesis of N1-ʹ’-
methylallylpyrimidine using Thymine (1.5 g, 11.89 mmol), BSA (7.2 ml, 29.73 mmol), 3-
bromo-2-methylpropene (2.40 ml, 23.79 mmol), NaI (1.96 g, 13.08 mmol) and TMSCl 
(1.51 ml, 11.89 mmol) in anhydrous acetonitrile (25 ml). After work up and evaporation, 
the compound was obtained as a pale yellow solid in quantitative yield (2.1 g). Rf = 0.45 
(EtOAc/Hexane - 7:3).1H NMR (500 MHz, CD3OD) δH: 7.34 (s, 1H, H-6), 4.98 (s, 1H, 
CH2=), 4.80 (s, 1H, CH2=), 4.30 (s, 2H, CH2-N), 1.89 (s, 3H, CH3, base), 1.76 (s, 3H, CH3, 
alkene). 
 
4.1.2.2 N1-2’-methylallyl-uracil (7) 
Prepared according to the standard procedure B for the synthesis of N1-ʹ’-
methylallylpyrimidine using Uracil (1.5 g, 13.38 mmol), BSA (8.18 ml, 33.46 mmol), 3-
bromo-2-methylpropene (2.70 ml, 26.76 mmol), NaI (2.21 g, 14.72 mmol) and TMSCl 
(1.70 ml, 13.38 mmol) in anhydrous acetonitrile (25 ml). After work up and evaporation, 
the mixture was purified by Biotage Isolera One (50 g SNAP cartridge ULTRA, 100 
ml/min, gradient eluent system EtOAc/Hexane 17% 1CV, 17-100% 10CV, 100% 3CV), to 
afford the title compound as a pale yellow solid (1.2 g, 51%). Rf = 0.25 (EtOAc/Hexane - 
7:3).1H NMR (500 MHz, CD3OD) δH: 7.50 (d, J = 7.8 Hz, 1H, H-6), 5.71 (d, J = 7.8 Hz, 1H, 
H-5), 4.98 (s, 1H, CH2=), 4.81 (s, 1H, CH2=), 4.33 (s, 2H, CH2-N), 1.76 (s, 3H, CH3, alkene). 
 
4.1.3 General procedure C for the preparation of (E)-N1-(4’-O-Aryl-(L-Alanine-ester)-
phosphinyl-2’-methyl-but-2’-enyl)pyrimidine (E-8a-f, E-10a-f) 
To a solution of O-Aryl-(L-Alanine-ester)-allylphosphonate (1 eq) and N1-ʹ’-
methylallylpyrimidine (2 eq) in dry CH2Cl2 (20 ml / mmol allylphosphonate), was added 
Hoveyda-Grubbs 2nd generation catalyst (15 mol%). The catalyst was added in three 
equal portion of 5 mol% at t = 0, 2, 4 h over the course of the reaction. The solution was 
sonicated under argon atmosphere for 24 h. Volatiles were then evaporated, and the 
residue was purified by Biotage Isolera One. Also a reverse phase chromatography was 
necessary to gain pure final products. 
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4.1.3.1 (E)-N1-(4’-O-(1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)thymine (E-8a) and (Z)-N1-(4’-O-(1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-
2’-methyl-but-2’-enyl)thymine (Z-8a) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate 3a (150 mg, 415 µmol) and 
N1-ʹ’-methylallylthymine (150 mg, 830.1 µmol) and Hoveyda-Grubbs 2nd generation 
catalyst (15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by 
Biotage Isolera One (50 g SNAP cartridge ULTRA, 100 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by reverse Biotage Isolera One (60 g 
SNAP cartridge KP-C18-HS, 100 ml/min, isocratic eluent system CH3CN/H2O 30-60% 
12CV) to afford the title compound E as pale yellow foamy solid (75 mg, 36%). Rf = 0.23 
(CH2Cl2/MeOH - 95:5).31P NMR (202 MHz, CD3OD) δP: 30.32, 29.54. 1H NMR (500 MHz, 
CD3OD) δH: 8.13-8.12 (m, 1H, ArH), 7.89-7.87 (m, 1H, ArH), 7.71-7.68 (m, 1H, ArH), 7.57-
7.48 (m, 3H, ArH), 7.45-7.39 (m, 1H, ArH), 7.27 (s, 0.5H, H-6), 7.26 (s, 0.5H, H-6), 5.61-
5.56 (m, 1H, CH=), 4.93-4.84 (m, 1H, CH(CH3)2), 4.32-4.26 (m, 2H, CH2-N), 4.01-3.91 (m, 
1H, CHCH3 L-Ala), 3.08-2.86 (m, 2H, CH2P), 1.75 (s, 3H, CH3, base), 1.67 (s, 3H, CH3, 
alkene), 1.27 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1.20-1.16 (m, 4.5H, CHCH3 L-Ala, 
CH(CH3)2), 1.13-1.10 (m, 3H, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.5 (d, 3JC-P = 
3.9 Hz, C=O, ester), 173.1 (d, 3JC-P = 3.5 Hz, C=O, ester), 165.34 (C-4), 165.32 (C-4), 151.69 
(C-2), 151.61 (C-2), 146.5 (d, 2JC-P = 9.5 Hz, C-O, Ph), 146.3 (d, 2JC-P = 9.5 Hz, C-O, Ph), 
140.94 (C-6), 140.92 (C-6), 135.5 (d, 3JC-P = 14.3 Hz, C=), 135.1 (d, 3JC-P = 14.7 Hz, C=), 
134.9 (C-Ar), 127.48 (CH-Ar), 127.46 (CH-Ar), 126.7 (d, 3JC-P = 5.1 Hz C-Ar), 126.6 (d, 3JC-P 
= 5.1 Hz C-Ar), 126.3 (CH-Ar), 126.0 (CH-Ar), 125.16 (CH-Ar), 125.11 (CH-Ar), 124.3 (CH-
Ar), 124.2 (CH-Ar), 121.4 (CH-Ar), 121.3 (CH-Ar), 117.1 (2JC-P = 11.1 Hz, CH=), 116.6 (2JC-P 
= 10.7 Hz, CH=), 115.3 (d, 3JC-P = 3.5 Hz CH-Ar), 115.1 (d, 3JC-P = 3.9 Hz CH-Ar), 110.1 (C-5), 
68.69 (CH(CH3)2), 68.65 (CH(CH3)2), 53.5 (d, 4JC-P = 2.7 Hz, CH2-N), 53.2 (d, 4JC-P = 2.3 Hz, 
CH2-N), 49.7 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 28.3 (d, 1JC-P = 129.0 Hz CH2P), 28.1 (d, 
1JC-P = 130.0 Hz CH2P), 20.55 (CH(CH3)2), 20.54 (CH(CH3)2), 20.48 (CH(CH3)2), 20.40 
(CH(CH3)2), 19.8 (d, 3JC-P = 5.5 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.9 Hz, CHCH3 L-Ala), 13.3 
(d, 4JC-P = 2.3 Hz, CH3, alkene), 13.2 (d, 4JC-P = 2.7 Hz, CH3, alkene), 10.8 (CH3, base). HPLC: 
Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳ͸.ʹ͸ min. 
HRMS (ESI): m/z [M+Na]+ calcd for C26H32N3O6P: 536.1926, found: 536.1921. 
From PrepHPLC also the Z isomer Z-8a was isolated as pale yellow foamy solid (6 mg, 
3%).31P NMR (202 MHz, CD3OD) δP: 30.40, 29.66. 1H NMR (500 MHz, CD3OD) δH: 
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8.19-8.13 (m, 1H, ArH), 7.90-7.85 (m, 1H, ArH), 7.78-7.67 (m, 1H, ArH), 7.57-7.43 (m, 5H, 
ArH, H-6), 5.73-5.65 (m, 1H, CH=), 4.97-4.86 (m, 1H, CH(CH3)2), 4.49 (bs, 2H, CH2-
N),4.04-3.98 (m, 1H, CHCH3 L-Ala), 3.24-3.07 (m, 2H, CH2P), 1.76-1.70 (m 6H, CH3, base; 
CH3, alkene), 1.27 (d, J = 7.0 Hz, 1.5H, CHCH3 L-Ala), 1.21-1.12 (m, 7.5H, CHCH3 L-Ala, 
CH(CH3)2, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.5 (d, 3JC-P = 3.9 Hz, C=O, ester), 
173.1 (d, 3JC-P = 3.5 Hz, C=O, ester), 165.3 (C-4), 151.8 (C-2), 151.7 (C-2), 146.4 (d, 2JC-P = 
10.2 Hz, C-O, Ph), 146.2 (d, 2JC-P = 10.8 Hz, C-O, Ph), 1401.1 (C-6), 141.0 (C-6), 134.9 (C-
Ar), 134.8 (d, 3JC-P = 14.6 Hz, C=), 134.5 (d, 3JC-P = 14.6 Hz, C=), 127.4 (CH-Ar), 126.9 (d, 3JC-
P = 4.8 Hz C-Ar), 126.8 (d, 3JC-P = 5.3 Hz C-Ar), 126.3 (CH-Ar), 126.04 (CH-Ar), 126.01 (CH-
Ar), 125.156 (CH-Ar), 125.12 (CH-Ar), 124.5 (CH-Ar), 124.4 (CH-Ar), 121.5 (CH-Ar), 
121.4 (CH-Ar), 119.1 (2JC-P = 11.1 Hz, CH=), 119.0 (2JC-P = 10.4 Hz, CH=), 115.7 (d, 3JC-P = 
3.4 Hz CH-Ar), 115.4 (d, 3JC-P = 3.4 Hz CH-Ar), 110.0 (C-5), 68.6 (CH(CH3)2), 49.7 (CHCH3 
L-Ala), 49.5 (CHCH3 L-Ala), 47.1 (CH2-N), 28.2 (d, 1JC-P = 129.0 Hz CH2P), 28.0 (d, 1JC-P = 
129.8 Hz CH2P), 20.51 (CH(CH3)2), 20.50 (CH(CH3)2), 20.4 (CH(CH3)2), 20.3 (CH(CH3)2), 
19.8 (d, 3JC-P = 5.5 Hz, CHCH3 L-Ala), 19.0 (d, 3JC-P = 5.5 Hz, CHCH3 L-Ala), 10.7 (d, 4JC-P = 3.0 
Hz, CH3, alkene), 10.6 (CH3, base). HPLC: Reverse phase HPLC eluting with gradient 
method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ 
nm, showed one peak with Rt 17.90 min. 
 
4.1.3.2 (E)-N1-(4’-O-(1-naphthyl)-(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)thymine (E-8b) 
Prepared according to the standard procedure C for the synthesis of ANP |ProTide using 
O-(1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate 3b (240 mg, 586.1 µmol) and 
N1-ʹ’-methylallylthymine (211 mg, 1.17 mmol) and Hoveyda-Grubbs 2nd generation 
catalyst (15 mol%) in dry CH2Cl2 (10 ml). After evaporation, the crude was purified by 
Biotage Isolera One (120 g ZIP cartridge KP-SIL, 100 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 40/60, 30 minutes), to afford the title compound as pale 
yellow foamy solid (43 mg, 13%). Rf = 0.40 (CH2Cl2/MeOH - 95:5).31P NMR (202 MHz, 
CD3OD) δP: 30.35, 29.51. 1H NMR (500 MHz, CD3OD) δH: 8.12-8.10 (m, 1H, ArH), 7.88-
7.87 (m, 1H, ArH), 7.70-7.66 (m, 1H, ArH), 7.54-7.22 (m, 10H, ArH), 5.53-5.45 (m, 1H, 
CH=), 5.12, 5.06 (ABq, JAB = 12.2 Hz, 1H, CH2Ph), 4.99, 4.95 (ABq, JAB = 12.2 Hz, 1H, 
CH2Ph), 4.26-4.20 (m, 2H, CH2-N), 4.11-4.06 (m, 1H, CHCH3 L-Ala), 3.02-2.86 (m, 2H, 
CH2P), 1.74 (s, 3H, CH3, base), 1.64 (d, J = 3.6 Hz 1.5H, CH3, alkene), 1.61 (d, J = 3.5 Hz 
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1.5H, CH3, alkene), 1.26 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1.18 (d, J = 7.2 Hz, 1.5H, CHCH3 
L-Ala). 13C NMR (125 MHz, CD3OD) δC: 173.7 (d, 3JC-P = 3.8 Hz, C=O, ester), 173.3 (d, 3JC-P 
= 3.7 Hz, C=O, ester), 165.35 (C-4), 165.32 (C-4), 151.67 (C-2), 151.60 (C-2), 146.5 (d, 2JC-
P = 9.7 Hz, C-O, Ph), 146.3 (d, 2JC-P = 9.9 Hz, C-O, Ph), 140.9 (C-6), 135.8 (C-Ar), 135.7 (C-
Ar), 135.4 (d, 3JC-P = 14.4 Hz, C=), 135.2 (d, 3JC-P = 14.7 Hz, C=), 134.9 (C-Ar), 128.19 (CH-
Ar), 128.12 (CH-Ar), 127.9 (CH-Ar), 127.8 (CH-Ar), 127.5 (CH-Ar), 127.4 (CH-Ar), 126.7 
(d, 3JC-P = 5.0 Hz C-Ar), 126.6 (d, 3JC-P = 5.3 Hz C-Ar), 126.3 (CH-Ar), 126.0 (CH-Ar), 125.19 
(CH-Ar), 125.11 (CH-Ar), 124.3 (CH-Ar), 124.2 (CH-Ar), 121.4 (CH-Ar), 121.2 (CH-Ar), 
117.1 (2JC-P = 10.7 Hz, CH=), 116.6 (2JC-P = 10.7 Hz, CH=), 115.4 (d, 3JC-P = 4.0 Hz CH-Ar), 
115.1 (d, 3JC-P = 3.6 Hz CH-Ar), 110.1 (C-5), 66.5 (CH2Ph), 66.4 (CH2Ph), 53.4 (d, 4JC-P = 2.0 
Hz, CH2-N), 53.2 (d, 4JC-P = 2.2 Hz, CH2-N), 49.6 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 28.3 
(d, 1JC-P = 129.3 Hz CH2P), 28.1 (d, 1JC-P = 130.2 Hz CH2P), 19.6 (d, 3JC-P = 5.6 Hz, CHCH3 L-
Ala), 19.0 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 13.3 (d, 4JC-P = 2.4 Hz, CH3, alkene), 13.2 (d, 4JC-P 
= 2.4 Hz, CH3, alkene), 10.8 (CH3, base). HPLC: Reverse phase HPLC eluting with gradient 
method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ 
nm, showed one peak with Rt 18.01 min. HRMS (ESI): m/z [M+Na]+ calcd for  
C30H32N3O6P: 584.1926, found: 584.1921. 
 
4.1.3.3 (E)-N1-(4’-O-Phenyl-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)thymine (E-8c) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-phenyl-(isopropyloxy-L-Alanine)-allylphosphonate 3c (140 mg, 449.7 µmol) and N1-ʹ’-methylallylthymine (162 mg, 899.4 µmol) and Hoveyda-Grubbs 2nd generation 
catalyst (15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by 
Biotage Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, gradient 
eluting system CH3CN/H2O from 10/90 to 100/0, 30 minutes), to afford the title 
compound as pale yellow foamy solid (20.4 mg, 10%). Rf = 0.27 (CH2Cl2/MeOH - 94:6). 
31P NMR (202 MHz, CD3OD) δP: 29.80, 29.03. 1H NMR (500 MHz, CD3OD) δH: 7.38-7.33 
(m, 3H, H-6, ArH), 7.22-7.16 (m, 3H, ArH), 5.52 (q, J = 6.9 Hz, 0.4H, CH=), 5.43 (q, J = 6.9 
Hz, 0.6H, CH=), 4.98 (sept, J = 6.2 Hz, 0.4H, CH(CH3)2), 4.92 (sept, J = 6.2 Hz, 0.6H, 
CH(CH3)2), 4.36-4.30 (m, 2H, CH2-N), 3.97-3.91 (m, 1H, CHCH3 L-Ala), 2.96-2.77 (m, 2H, 
CH2P), 1.85 (s, 3H, CH3, base), 1.72 (s, 1.2H, CH3, alkene), 1.71 (s, 1.8H, CH3, alkene),1.29 
(d, J = 6.9 Hz, 1.8H, CHCH3 L-Ala), 1.25 (d, J = 6.3 Hz, 1.2H, CH(CH3)2), 1.23 (d, J = 6.2 Hz, 
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1.2H, CH(CH3)2), 1.21-1.96 (m, 4.8H, CHCH3 L-Ala, CH(CH3)2). 13C NMR (125 MHz, 
CD3OD) δC: 173.6 (d, 3JC-P = 4.6 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.1 Hz, C=O, ester), 165.3 
(C-4), 151.7 (C-2), 151.6 (C-2), 150.5 (d, 2JC-P = 9.8 Hz, C-O, Ph), 150.3 (d, 2JC-P = 9.5 Hz, C-
O, Ph), 141.0 (C-6), 135.4 (d, 3JC-P = 14.4 Hz, C=), 135.0 (d, 3JC-P = 14.4 Hz, C=), 129.32 (CH-
Ar), 129.30 (CH-Ar), 124.5 (CH-Ar), 124.4 (CH-Ar), 120.6 (d, 3JC-P = 4.3 Hz CH-Ar), 120.4 
(d, 3JC-P = 4.6 Hz CH-Ar), 117.2 (d, 2JC-P = 11.0 Hz, CH=), 116.6 (d, 2JC-P = 10.8 Hz, CH=), 
110.1 (C-5), 68.67 (CH(CH3)2), 68.63 (CH(CH3)2), 53.5 (d, 4JC-P = 2.4 Hz, CH2-N), 53.3 (d, 
4JC-P = 2.4 Hz, CH2-N), 49.6 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 28.2 (d, 1JC-P = 129.5 Hz, 
CH2P), 28.0 (d, 1JC-P = 130.5 Hz, CH2P), 20.58 (CH(CH3)2), 20.53 (CH(CH3)2), 20.4 
(CH(CH3)2), 19.8 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala),13.2 
(d, 4JC-P = 2.5 Hz, CH3, alkene), 13.1 (d, 4JC-P = 2.2 Hz, CH3, alkene), 10.8 (CH3, base). HPLC: 
Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳ͵.9Ͷ min. 
HRMS (ESI): m/z [M+Na]+ calcd for C22H30N3O6P: 486.1770, found: 486.1764. 
 
4.1.3.4 (E)-N1-(4’-O-Phenyl-(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)thymine (E-8d) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-phenyl-(benzyloxy-L-Alanine)-allylphosphonate 3d (200 mg, 556.5 µmol) and N1-ʹ’-
methylallylthymine (200.6 mg, 1.11 mmol) and Hoveyda-Grubbs 2nd generation catalyst 
(15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by Biotage 
Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent system 2-
propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 35/65, 30 minutes), to afford the title compound as pale 
yellow foamy solid (64 mg, 23%). Rf = 0.42 (CH2Cl2/2-propanol - 95:5).31P NMR (202 
MHz, CD3OD) δP: 29.79, 28.99. 1H NMR (500 MHz, CD3OD) δH: 7.36-7.29 (m, 8H, H-6, 
ArH), 7.20-7.14 (m, 3H, ArH), 5.49-5.40 (m, 1H, CH=), 5.16, 5.13 (ABq, JAB = 12.3 Hz, 1H, 
CH2Ph), 5.08 (s app, 1H, CH2Ph), 4.28-4.23 (m, 2H, CH2-N), 4.07-4.01 (m, 1H, CHCH3 L-
Ala), 2.89-2.73 (m, 2H, CH2P), 1.84 (s, 3H, CH3, base), 1.67-1.64 (m, 3H, CH3, alkene), 1.30 
(d, J = 7.0 Hz, 1.5H, CHCH3 L-Ala), 1.22 (d, J = 7.1 Hz, 1.5H, CHCH3 L-Ala). 13C NMR (125 
MHz, CD3OD) δC: 173.8 (d, 3JC-P = 4.5 Hz, C=O, ester), 173.4 (d, 3JC-P = 3.9 Hz, C=O, ester), 
165.3 (C-4), 151.7 (C-2), 151.6 (C-2), 150.5 (d, 2JC-P = 9.3 Hz, C-O, Ph), 150.4 (d, 2JC-P = 9.4 
Hz, C-O, Ph), 140.98 (C-6), 140.97 (C-6), 135.9 (C-Ar), 135.8 (C-Ar), 135.3 (d, 3JC-P = 14.1 
Hz, C=), 135.0 (d, 3JC-P = 14.0 Hz, C=), 129.35 (CH-Ar), 129.34 (CH-Ar), 128.23 (CH-Ar), 
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128.20 (CH-Ar), 128.01 (CH-Ar), 128.00 (CH-Ar), 127.96 (CH-Ar), 127.95 (CH-Ar), 124.6 
(CH-Ar), 124.5 (CH-Ar), 120.6 (d, 3JC-P = 4.3 Hz CH-Ar), 120.4 (d, 3JC-P = 3.8 Hz CH-Ar), 
117.2 (d, 2JC-P = 10.7 Hz, CH=), 116.6 (d, 2JC-P = 10.7 Hz, CH=), 110.13 (C-5), 110.11 (C-5), 
65.5 (CH2Ph), 66.4 (CH2Ph), 53.5 (d, 4JC-P = 2.4 Hz, CH2-N), 53.3 (d, 4JC-P = 2.3 Hz, CH2-N), 
49.6 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 28.2 (d, 1JC-P = 129.7 Hz, CH2P), 28.0 (d, 1JC-P = 
130.3 Hz, CH2P), 19.7 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.3 Hz, CHCH3 L-Ala), 
13.3 (d, 4JC-P = 1.8 Hz, CH3, alkene), 13.1 (d, 4JC-P = 2.2 Hz, CH3, alkene), 10.9 (CH3, base). 
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳͷ.ʹͳ 
min. HRMS (ESI): m/z [M+Na]+ calcd for C26H30N3O6P: 534.1764, found: 534.1764. 
 
4.1.3.5 (E)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-
2’-methyl-but-2’-enyl)thymine (E-8e) and (Z)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-
(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-enyl)thymine (Z-8e) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(5,6,7,8-tetrahydro-1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate 3e (200 
mg, 547.3 µmol) and N1-ʹ’-methylallylthymine (197 mg, 1.09 mmol) and Hoveyda-
Grubbs 2nd generation catalyst (15 mol%) in dry CH2Cl2 (10 ml). After evaporation, the 
crude was purified by Biotage Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, 
gradient eluent system 2-propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a 
mixture of the E and Z isomers. The two isomers were then separated by PrepHPLC (20 
ml/min, isocratic eluting system CH3CN/H2O - 35/65, 30 minutes), to afford the title 
compound E as pale yellow foamy solid (72 mg, 26%). Rf = 0.26 (CH2Cl2/2-propanol - 
95:5). 31P NMR (202 MHz, CD3OD) δP: 29.35, 28.55. 1H NMR (500 MHz, CD3OD) δH: 
7.34 (s, 0.5H, H-6), 7.33 (s, 0.5H, H-6), 7.17-7.12 (m, 1H, ArH), 7.05-7.00 (m, 1H, ArH), 
6.89-6.86 (m, 1H, ArH), 5.57-5.52 (m, 0.5H, CH=), 5.50-5.44 (m, 0.5H, CH=), 5.01-4.88 (m, 
1H, CH(CH3)2), 4.36-4.29 (m, 2H, CH2-N), 3.99-3.91 (m, 1H, CHCH3 L-Ala), 2.94-2.82 (m, 
2H, CH2P), 2.77-2.74 (m, 2H, ArH), 2.69-2.67 (m, 2H, ArH), 1.84 (s, 3H, CH3, base), 1.80-
1.76 (m, 4H, ArH), 1.70 (d, J = 2.9 Hz 3H, CH3, alkene), 1.29 (d, J = 7.2 Hz, 1.5H, CHCH3 L-
Ala), 1.25-1.24 (m, 4.5H, CHCH3 L-Ala, CH(CH3)2), 1.19 (d, J = 6.2 Hz, 3H, CH(CH3)2). 13C 
NMR (125 MHz, CD3OD) δC: 173.7 (d, 3JC-P = 3.8 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.1 Hz, 
C=O, ester), 165.3 (C-4), 151.7 (C-2), 151.6 (C-2), 148.8 (d, 2JC-P = 9.4 Hz, C-O, Ph), 148.7 
(d, 2JC-P = 9.9 Hz, C-O, Ph), 141.05 (C-6), 141.02 (C-6), 139.19 (C-Ar), 139.16 (C-Ar), 135.1 
(d, 3JC-P = 14.1 Hz, C=), 134.8 (d, 3JC-P = 14.3 Hz, C=), 128.4 (d, 3JC-P = 5.5 Hz C-Ar), 128.3 (d, 
3JC-P = 5.8 Hz C-Ar), 125.4 (CH-Ar), 125.3 (CH-Ar), 125.1 (CH-Ar), 125.0 (CH-Ar), 117.4 
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(2JC-P = 11.0 Hz, CH=), 116.9 (2JC-P = 10.2 Hz, CH=), 116.8 (d, 3JC-P = 4.4 Hz CH-Ar), 116.7 (d, 
3JC-P = 3.3 Hz CH-Ar), 110.1 (C-5), 110.1 (C-5), 68.66 (CH(CH3)2), 68.62 (CH(CH3)2), 53.6 
(d, 4JC-P = 2.4 Hz, CH2-N), 53.3 (d, 4JC-P = 2.4 Hz, CH2-N), 49.7 (CHCH3 L-Ala), 49.5 (CHCH3 
L-Ala), 29.1 (CH2-Ar), 28.5 (d, 1JC-P = 129.8 Hz CH2P), 28.2 (d, 1JC-P = 131.2 Hz CH2P), 23.5 
(CH2-Ar), 22.47 (CH2-Ar), 22.44 (CH2-Ar), 22.42 (CH2-Ar), 20.6 (CH(CH3)2), 20.56 
(CH(CH3)2), 20.55 (CH(CH3)2), 20.4 (CH(CH3)2), 19.9 (d, 3JC-P = 5.2 Hz, CHCH3 L-Ala), 19.1 
(d, 3JC-P = 5.8 Hz, CHCH3 L-Ala), 13.3 (d, 4JC-P = 2.4 Hz, CH3, alkene), 13.2 (d, 4JC-P = 2.2 Hz, 
CH3, alkene), 10.8 (CH3, base). HPLC: Reverse phase HPLC eluting with gradient method 
CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, 
showed one peak with Rt 16.85 min. HRMS (ESI): m/z [M+Na]+ calcd for C26H36N3O6P: 
540.2239, found: 540.2234. 
From PrepHPLC also the Z isomer Z-8e was isolated as pale yellow foamy solid (7 mg, 
3%). 31P NMR (202 MHz, CD3OD) δP: 29.41, 28.64. 1H NMR (500 MHz, CD3OD) δH: 7.33 
(s, 1H, H-6), 7.05-7.00 (m, 1H, ArH), 6.95-6.89 (m, 1H, ArH), 6.80-6.76 (m, 1H, ArH), 
5.53-5.48 (m, 1H, CH=), 4.88-4.77 (m, 1H, CH(CH3)2), 4.38-4.27 (m, 2H, CH2-N), 3.86-3.81 
(m, 1H, CHCH3 L-Ala), 2.98-2.82 (m, 2H, CH2P), 2.65-2.62 (m, 4H, ArH), 1.71-1.68 (m, 7H, 
ArH, CH3, base), 1.61-1.60 (m, 3H, CH3, alkene), 1.20-1.07 (m, 9H, CHCH3 L-Ala, 
CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.7 (d, 3JC-P = 3.8 Hz, C=O, ester), 173.3 (d, 
3JC-P = 3.8 Hz, C=O, ester), 165.3 (C-4), 151.7 (C-2), 151.6 (C-2), 148.8 (d, 2JC-P = 9.5 Hz, C-
O, Ph), 148.7 (d, 2JC-P = 9.9 Hz, C-O, Ph), 141.05 (C-6), 141.02 (C-6), 139.19 (C-Ar), 139.16 
(C-Ar), 135.1 (d, 3JC-P = 14.2 Hz, C=), 134.8 (d, 3JC-P = 14.2 Hz, C=), 128.4 (d, 3JC-P = 5.1 Hz C-
Ar), 128.3 (d, 3JC-P = 5.6 Hz C-Ar), 125.4 (CH-Ar), 125.3 (CH-Ar), 125.1 (CH-Ar), 125.0 (CH-
Ar), 119.3 (2JC-P = 11.3 Hz, CH=), 119.2 (2JC-P = 11.0 Hz, CH=), 117.2 (d, 3JC-P = 3.5 Hz CH-
Ar), 117.0 (d, 3JC-P = 3.5 Hz CH-Ar), 110.0 (C-5), 68.66 (CH(CH3)2), 68.63 (CH(CH3)2), 49.7 
(CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 47.3 (CH2-N), 29.1 (CH2-Ar), 28.5 (d, 1JC-P = 129.8 Hz 
CH2P), 28.2 (d, 1JC-P = 131.2 Hz CH2P), 26.4 (CH2-Ar), 26.3 (CH2-Ar), 25.8 (CH2-Ar), 25.7 
(CH2-Ar), 20.5 (CH3, alkene), 20.4 (CH3, alkene), 19.97 (CH(CH3)2), 19.93 (CH(CH3)2), 19.7 
(d, 3JC-P = 5.2 Hz, CHCH3 L-Ala), 19.0 (d, 3JC-P = 5.8 Hz, CHCH3 L-Ala), 10.7 (CH3, base). 
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳ͹.9Ͳ 
min. 
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4.1.3.6 (E)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-(benzyloxy-L-Alanine)-phosphinyl-2’-
methyl-but-2’-enyl)thymine (E-8f) and (Z)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-
(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-enyl)thymine (Z-8f) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(5,6,7,8-tetrahydro-1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate 3f (200 mg, 
483.7 µmol) and N1-ʹ’-methylallylthymine (174 mg, 967.4 µmol) and Hoveyda-Grubbs 
2nd generation catalyst (15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was 
purified by Biotage Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent 
system 2-propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E 
and Z isomers. The two isomers were then separated by reverse Biotage Isolera One (60 
g SNAP cartridge KP-C18-HS, 100 ml/min, isocratic eluent system CH3CN/H2O 30-60% 
12CV) to afford the title compound E as pale yellow foamy solid (36 mg, 14%). Rf = 0.23 
(CH2Cl2/2-propanol - 95:5). 31P NMR (202 MHz, CD3OD) δP: 29.36, 28.51. 1H NMR (500 
MHz, CD3OD) δH: 7.36-7.28 (m, 6H, H-6, ArH), 7.16-7.12 (m, 1H, ArH), 7.04-6.95 (m, 1H, 
ArH), 6.89-6.85 (m, 1H, ArH), 5.49-5.42 (m, 1H, CH=), 5.15, 5.12 (ABq, JAB = 12.2 Hz, 1H, 
CH2Ph), 5.07, 5.05 (ABq, JAB = 12.6 Hz, 1H, CH2Ph), 4.31-4.22 (m, 2H, CH2-N), 4.09-4.00 
(m, 1H, CHCH3 L-Ala), 2.90-2.77 (m, 2H, CH2P), 2.74 (bs, 2H, ArH), 2.66 (bs, 2H, ArH), 
1.83 (s, 3H, CH3, base), 1.76-1.75 (m, 4H, ArH), 1.66 (d, J = 2.9 Hz 1.8H, CH3, alkene), 1.64 
(d, J = 3.1 Hz 1.2H, CH3, alkene), 1.31 (d, J = 7.0 Hz, 1.5H, CHCH3 L-Ala), 1.26 (d, J = 7.1 Hz, 
1.5H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 173.8 (d, 3JC-P = 3.8 Hz, C=O, ester), 
173.4 (d, 3JC-P = 3.5 Hz, C=O, ester), 165.38 (C-4), 165.37 (C-4), 151.7 (C-2), 151.6 (C-2), 
148.8 (d, 2JC-P = 9.8 Hz, C-O, Ph), 148.7 (d, 2JC-P = 9.5 Hz, C-O, Ph), 140.9 (C-6), 139.2 (C-
Ar), 139.1 (C-Ar), 135.9 (C-Ar), 135.8 (C-Ar), 135.1 (d, 3JC-P = 14.5 Hz, C=), 134.8 (d, 3JC-P = 
13.9 Hz, C=), 128.4 (d, 3JC-P = 5.4 Hz C-Ar), 128.3 (d, 3JC-P = 5.7 Hz C-Ar), 128.2 (CH-Ar), 
128.1 (CH-Ar), 127.96 (CH-Ar), 127.92 (CH-Ar), 127.8 (CH-Ar), 125.4 (CH-Ar), 125.3 (CH-
Ar), 125.1 (CH-Ar), 125.0 (CH-Ar), 117.4 (2JC-P = 10.9 Hz, CH=), 116.8 (2JC-P = 10.4 Hz, 
CH=), 116.7 (d, 3JC-P = 3.2 Hz CH-Ar), 116.6 (d, 3JC-P = 3.2 Hz CH-Ar), 110.09 (C-5), 110.06 
(C-5), 66.5 (CH2Ph), 66.4 (CH2Ph), 53.5 (d, 4JC-P = 2.1 Hz, CH2-N), 53.3 (d, 4JC-P = 2.4 Hz, 
CH2-N), 49.6 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 29.1 (CH2-Ar), 28.2 (d, 1JC-P = 130.8 Hz 
CH2P), 28.2 (d, 1JC-P = 130.8 Hz CH2P), 23.3 (CH2-Ar), 22.45 (CH2-Ar), 22.43 (CH2-Ar), 
22.40 (CH2-Ar), 19.7-19.6 (m, CHCH3 L-Ala, CH3, alkene), 19.0 (d, 3JC-P = 5.7 Hz, CHCH3 L-
Ala), 10.8 (CH3, base). HPLC: Reverse phase HPLC eluting with gradient method 
CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, 
showed one peak with Rt 18.44 min. HRMS (ESI): m/z [M+Na]+ calcd for C30H36N3O6P: 
588.2239, found: 588.2234. 
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From PrepHPLC also the Z isomer Z-8f was isolated as pale yellow foamy solid (18 mg, 
7%). 31P NMR (202 MHz, CD3OD) δP: 29.38, 28.63. 1H NMR (500 MHz, CD3OD) δH: 
7.42-7.33 (m, 6H, H-6, ArH), 7.15-7.12 (m, 1H, ArH), 7.07-6.95 (m, 1H, ArH), 6.92-6.86 
(m, 1H, ArH), 5.60-5.55 (m, 1H, CH=), 5.15 (AB app s, 1H, CH2Ph), 5.07 (AB app s, 1H, 
CH2Ph), 4.46-4.26 (m, 2H, CH2-N), 4.11-4.03 (m, 1H, CHCH3 L-Ala), 3.07-2.90 (m, 2H, 
CH2P), 2.76-2.70 (m, 4H, ArH), 1.83-1.77 (m, 7H, ArH, CH3, base), 1.69 (d, J = 5.2 Hz 1.8H, 
CH3, alkene), 1.66 (d, J = 5.2 Hz 1.2H, CH3, alkene), 1.34 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 
1.24 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 173.8 (d, 3JC-P = 
3.8 Hz, C=O, ester), 173.4 (d, 3JC-P = 3.5 Hz, C=O, ester), 165.3 (C-4), 151.7 (C-2), 148.8 (d, 
2JC-P = 9.2 Hz, C-O, Ph), 148.7 (d, 2JC-P = 9.2 Hz, C-O, Ph), 141.1 (C-6), 141.0 (C-6), 139.25 
(C-Ar), 139.21 (C-Ar), 135.9 (C-Ar), 135.8 (C-Ar), 134.4 (d, 3JC-P = 14.3 Hz, C=), 134.2 (d, 
3JC-P = 13.5 Hz, C=), 128.7 (d, 3JC-P = 5.9 Hz C-Ar), 128.6 (d, 3JC-P = 5.0 Hz C-Ar), 128.18 (CH-
Ar), 128.15 (CH-Ar), 127.94 (CH-Ar), 127.91 (CH-Ar), 127.87 (CH-Ar), 127.84 (CH-Ar), 
125.4 (CH-Ar), 125.3 (CH-Ar), 125.2 (CH-Ar), 125.0 (CH-Ar), 119.2 (2JC-P = 10.9 Hz, CH=), 
119.0 (2JC-P = 11.8 Hz, CH=), 117.2 (d, 3JC-P = 3.3 Hz CH-Ar), 116.9 (d, 3JC-P = 2.5 Hz CH-Ar), 
110.05 (C-5), 110.02 (C-5), 66.5 (CH2Ph), 66.4 (CH2Ph), 49.7 (CHCH3 L-Ala), 49.5 (CHCH3 
L-Ala), 47.2 (CH2-N), 29.1 (CH2-Ar), 28.3 (d, 1JC-P = 129.4 Hz CH2P), 28.1 (d, 1JC-P = 130.2 Hz 
CH2P), 26.4 (CH2-Ar), 26.3 (CH2-Ar), 25.8 (CH2-Ar), 25.7 (CH2-Ar), 19.7-19.6 (m, CHCH3 L-
Ala, CH3, alkene), 18.8 (d, 3JC-P = 5.9 Hz, CHCH3 L-Ala), 10.7 (CH3, base). HPLC: Reverse 
phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in 30 minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳ9.͵ͳ min.  
 
4.1.3.7 (E)-N1-(4’-O-(1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)uracil (E-10a) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate 3a (150 mg, 415 µmol) and 
N1-ʹ’-methylallyluracil (137 mg, 830.1 µmol) and Hoveyda-Grubbs 2nd generation 
catalyst (15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by 
Biotage Isolera One (50 g SNAP cartridge ULTRA, 100 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 35/65, 30 minutes), to afford the title compound as pale 
yellow foamy solid (28 mg, 14%). Rf = 0.24 (CH2Cl2/MeOH - 96:4). 31P NMR (202 MHz, 
CD3OD) δP: 30.28, 29.49. 1H NMR (500 MHz, CD3OD) δH: 8.14-8.13 (m, 1H, ArH), 7.88-
7.84 (m, 1H, ArH), 7.70-7.67 (m, 1H, ArH), 7.58-7.49 (m, 3H, ArH), 7.44-7.38 (m, 2H, H-6, 
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ArH), 5.61-5.57 (m, 1.5H, CH=, H-5), 5.51-5.47 (m, 0.5H, CH=), 4.93 (sept, J = 6.5 Hz, 0.5H, 
CH(CH3)2), 4.88-4.84 (m, 0.5H, CH(CH3)2), 4.33-4.25 (m, 2H, CH2-N), 4.04-3.97 (m, 1H, 
CHCH3 L-Ala), 3.08-2.90 (m, 2H, CH2P), 1.65 (bs, 3H, CH3, alkene), 1.27 (d, J = 7.0 Hz, 
1.5H, CHCH3 L-Ala), 1.20 (d, J = 6.2 Hz, 1.5H, CH(CH3)2), 1.19 (d, J = 6.2 Hz, 1.5H, 
CH(CH3)2), 1.17 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1.12 (d, J = 6.2 Hz, 1.5H, CH(CH3)2), 
1.15 (d, J = 6.2 Hz, 1.5H, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.6 (d, 3JC-P = 4.3 
Hz, C=O, ester), 173.2 (d, 3JC-P = 4.1 Hz, C=O, ester), 165.17 (C-4), 165.15 (C-4), 151.5 (C-
2), 151.4 (C-2), 146.5 (d, 2JC-P = 9.7 Hz, C-O, Ph), 146.3 (d, 2JC-P = 9.7 Hz, C-O, Ph), 145.2 (C-
6), 145.1 (C-6), 135.2 (d, 3JC-P = 14.5 Hz, C=), 135.4 (d, 3JC-P = 14.5 Hz, C=), 134.9 (C-Ar), 
127.5 (CH-Ar), 127.4 (CH-Ar), 126.8 (d, 3JC-P = 4.9 Hz C-Ar), 126.6 (d, 3JC-P = 5.1 Hz C-Ar), 
126.3 (CH-Ar), 126.1 (CH-Ar), 125.2 (CH-Ar), 125.1 (CH-Ar), 124.3 (CH-Ar), 124.2 (CH-
Ar), 121.5 (CH-Ar), 121.3 (CH-Ar), 117.4 (2JC-P = 11.0 Hz, CH=), 116.9 (2JC-P = 11.0 Hz, 
CH=), 115.4 (d, 3JC-P = 3.8 Hz CH-Ar), 115.1 (d, 3JC-P = 3.8 Hz CH-Ar), 101.2 (C-5), 68.69 
(CH(CH3)2), 68.66 (CH(CH3)2), 53.7 (d, 4JC-P = 2.3 Hz, CH2-N), 53.5 (d, 4JC-P = 2.3 Hz, CH2-N), 
49.7 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 28.3 (d, 1JC-P = 128.9 Hz CH2P), 28.1 (d, 1JC-P = 
129.8 Hz CH2P), 20.6 (CH(CH3)2), 20.56 (CH(CH3)2), 20.52 (CH(CH3)2), 20.4 (CH(CH3)2), 
19.8 (d, 3JC-P = 5.8 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.5 Hz, CHCH3 L-Ala), 13.3 (d, 4JC-P = 2.4 
Hz, CH3, alkene), 13.2 (d, 4JC-P = 2.2 Hz, CH3, alkene). HPLC: Reverse phase HPLC eluting 
with gradient method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ 
nm and 263 nm, showed one peak with Rt 15.57 min. HRMS (ESI): m/z [M+Na]+ calcd 
for C25H30N3O6P: 522.1770, found: 522.1764.  
 
4.1.3.8 (E)-N1-(4’-O-(1-naphthyl)-(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)uracil (E-10b) 
 Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate 3b (240 mg, 586.1 µmol) and 
N1-ʹ’-methylallyluracil (195 mg, 1.17 mmol) and Hoveyda-Grubbs 2nd generation 
catalyst (15 mol%) in dry CH2Cl2 (10 ml). After evaporation, the crude was purified by 
Biotage Isolera One (120 g ZIP cartridge KP-SIL, 100 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 40/60, 30 minutes), to afford the title compound as pale 
yellow foamy solid (13 mg, 5%). Rf = 0.33 (CH2Cl2/MeOH - 95:5). 31P NMR (202 MHz, 
CD3OD) δP: 30.33, 29.48. 1H NMR (500 MHz, CD3OD) δH: 8.01-7.99 (m, 1H, ArH), 7.78-
7.64 (m, 1H, ArH), 7.59-7.55 (m, 1H, ArH), 7.44-7.13 (m, 10H, , H-6, ArH), 5.48 (d, J = 7.9 
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Hz, 1H, H-5), 5.42-5.34 (m, 1H, CH=), 5.01, 4.96 (ABq, JAB = 12.2 Hz, 1H, CH2Ph), 4.88, 4.84 
(ABq, JAB = 12.2 Hz, 1H, CH2Ph), 4.16 (bs, 2H, CH2-N), 4.00-3.94 (m, 1H, CHCH3 L-Ala), 
2.90-2.75 (m, 2H, CH2P), 1.51 (d, J = 3.4 Hz 1.5H, CH3, alkene), 1.49 (d, J = 3.5 Hz 1.5H, 
CH3, alkene), 1.15 (d, J = 7.0 Hz, 1.5H, CHCH3 L-Ala), 1.06 (d, J = 7.1 Hz, 1.5H, CHCH3 L-
Ala). 13C NMR (125 MHz, CD3OD) δC: 173.7 (d, 3JC-P = 4.3 Hz, C=O, ester), 173.3 (d, 3JC-P = 
4.1 Hz, C=O, ester), 163.5 (C-4), 151.5 (C-2), 151.4 (C-2), 146.5 (d, 2JC-P = 9.9 Hz, C-O, Ph), 
146.3 (d, 2JC-P = 9.7 Hz, C-O, Ph), 145.2 (C-6), 145.1 (C-6), 135.8 (C-Ar), 135.7 (C-Ar), 
135.3 (d, 3JC-P = 14.1 Hz, C=), 135.2 (d, 3JC-P = 14.8 Hz, C=), 134.9 (C-Ar), 128.18 (CH-Ar), 
128.10 (CH-Ar), 127.9 (CH-Ar), 127.8 (CH-Ar), 126.7 (d, 3JC-P = 4.9 Hz C-Ar), 126.6 (d, 3JC-P 
= 4.7 Hz C-Ar), 126.3 (CH-Ar), 126.08(CH-Ar), 126.06(CH-Ar), 125.17 (CH-Ar), 125.10 
(CH-Ar), 124.3 (CH-Ar), 124.2 (CH-Ar), 121.4 (CH-Ar), 121.3 (CH-Ar), 117.3 (2JC-P = 11.1 
Hz, CH=), 116.8 (2JC-P = 11.7 Hz, CH=), 115.17 (d, 3JC-P = 3.9 Hz CH-Ar), 115.10 (d, 3JC-P = 3.9 
Hz CH-Ar), 101.2 (C-5), 66.5 (CH2Ph), 66.4 (CH2Ph), 53.7 (d, 4JC-P = 2.6 Hz, CH2-N), 53.5 (d, 
4JC-P = 2.6 Hz, CH2-N), 49.6 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 28.2 (d, 1JC-P = 129.0 Hz 
CH2P), 28.0 (d, 1JC-P = 129.9 Hz CH2P), 19.6 (d, 3JC-P = 5.7 Hz, CHCH3 L-Ala), 18.9 (d, 3JC-P = 
5.7 Hz, CHCH3 L-Ala), 13.2 (d, 4JC-P = 2.4 Hz, CH3, alkene), 13.1 (d, 4JC-P = 2.4 Hz, CH3, 
alkene). HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with 
Rt 15.87 min. HRMS (ESI): m/z [M+Na]+ calcd for C29H30N3O6P: 570.1770, found: 
570.1764. 
 
4.1.3.9 (E)-N1-(4’-O-Phenyl-(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-
enyl)uracil (E-10c) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-phenyl-(isopropyloxy-L-Alanine)-allylphosphonate 3c (140 mg, 449.7 µmol) and N1-ʹ’-methylallyluracil (150 mg, 1.11 mmol) and Hoveyda-Grubbs 2nd generation catalyst 
(15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by Biotage 
Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent system 
MeOH/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, gradient 
eluting system CH3CN/H2O from 10/90 to 100/0, 30 minutes), to afford the title 
compound as pale yellow foamy solid (20 mg, 10%). Rf = 0.42 (CH2Cl2/MeOH - 95:5). 31P 
NMR (202 MHz, CD3OD) δP: 29.74, 28.97. 1H NMR (500 MHz, CD3OD) δH: 7.53 (d, J = 
7.8 Hz, 0.3H, H-6), 7.50 (d, J = 7.8 Hz, 0.7H, H-6), 7.38-7.33 (m, 2H, ArH), 7.23-7.16 (m, 
3H, ArH), 5.67 (d, J = 7.9 Hz, 1H, H-5), 5.54 (q, J = 7.0 Hz, 0.3H, CH=), 5.46 (q, J = 7.0 Hz, 
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0.7H, CH=), 5.02-4.89 (m, 1H, CH(CH3)2), 4.36-4.35 (m, 2H, CH2-N), 3.98-3.91 (m, 1H, 
CHCH3 L-Ala), 2.94-2.77 (m, 2H, CH2P), 1.72-1.71 (m, 3H, CH3, alkene), 1.29 (d, J = 7.0 Hz, 
2.1H, CHCH3 L-Ala), 1.25 (d, J = 6.7 Hz, 0.9H, CH(CH3)2), 1.23 (d, J = 6.2 Hz, 0.9H, 
CH(CH3)2), 1.21-1.19 (m, 5.1H, CHCH3 L-Ala, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 
173.5 (d, 3JC-P = 4.7 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.1 Hz, C=O, ester), 165.2 (C-4), 151.5 
(C-2), 151.4 (C-2), 150.6 (d, 2JC-P = 9.6 Hz, C-O, Ph), 150.4 (d, 2JC-P = 9.3 Hz, C-O, Ph), 
145.32 (C-6), 145.30 (C-6), 135.2 (d, 3JC-P = 14.5 Hz, C=), 134.8 (d, 3JC-P = 14.2 Hz, C=), 
129.3 (CH-Ar), 124.6 (CH-Ar), 124.4 (CH-Ar), 120.6 (d, 3JC-P = 4.6 Hz CH-Ar), 120.4 (d, 3JC-P 
= 4.3 Hz CH-Ar), 117.6 (d, 2JC-P = 11.2 Hz, CH=), 116.9 (d, 2JC-P = 10.7 Hz, CH=), 101.2 (C-5), 
68.67 (CH(CH3)2), 68.64 (CH(CH3)2), 53.8 (d, 4JC-P = 2.4 Hz, CH2-N), 53.5 (d, 4JC-P = 2.1 Hz, 
CH2-N), 49.6 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 28.2 (d, 1JC-P = 129.7 Hz, CH2P), 28.0 (d, 
1JC-P = 130.3 Hz, CH2P), 20.6 (CH(CH3)2), 20.5 (CH(CH3)2), 20.4 (CH(CH3)2), 19.8 (d, 3JC-P = 
5.4 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala),13.2 (d, 4JC-P = 2.4 Hz, CH3, 
alkene), 13.1 (d, 4JC-P = 2.4 Hz, CH3, alkene). HPLC: Reverse phase HPLC eluting with 
gradient method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm 
and 263 nm, showed one peak with Rt 13.16 min. HRMS (ESI): m/z [M+Na]+ calcd for 
C21H28N3O6P: 472.1613, found: 472.1608. 
 
4.1.3.10 (E)-N1-(4’-O-Phenyl-(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-enyl)uracil 
(E-10d) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-phenyl-(benzyloxy-L-Alanine)-allylphosphonate 3d (200 mg, 556.5 µmol) and N1-ʹ’-
methylallyluracil (184.9 mg, 1.11 mmol) and Hoveyda-Grubbs 2nd generation catalyst 
(15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was purified by Biotage 
Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent system 2-
propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z 
isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 35/65, 30 minutes), to afford the title compound as pale 
yellow foamy solid (49 mg, 18%). Rf = 0.42 (CH2Cl2/2-propanol - 95:5). 31P NMR (202 
MHz, CD3OD) δP: 29.75, 28.94. 1H NMR (500 MHz, CD3OD) δH: 7.46 (d, J = 7.8 Hz, 1H, H-
6), 7.37-7.29 (m, 7H, ArH), 7.20-7.14 (m, 3H, ArH), 5.67 (d, J = 7.8 Hz, 1H, H-5), 5.50-5.40 
(m, 1H, CH=), 5.17, 5.14 (ABq, JAB = 12.3 Hz, 1H, CH2Ph), 5.08 (s app, 1H, CH2Ph), 4.31-
4.29 (m, 2H, CH2-N), 4.08-4.04 (m, 1H, CHCH3 L-Ala), 2.89-2.74 (m, 2H, CH2P), 1.67-1.65 
(m, 3H, CH3, alkene), 1.30 (d, J = 6.9 Hz, 1.5H, CHCH3 L-Ala), 1.22 (d, J = 7.2 Hz, 1.5H, 
CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 173.8 (d, 3JC-P = 4.4 Hz, C=O, ester), 173.4 
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(d, 3JC-P = 3.9 Hz, C=O, ester), 165.2 (C-4), 151.5 (C-2), 150.5 (d, 2JC-P = 9.2 Hz, C-O, Ph), 
150.3 (d, 2JC-P = 10.0 Hz, C-O, Ph), 145.2 (C-6), 135.8 (C-Ar), 135.1 (d, 3JC-P = 14.4 Hz, C=), 
134.8 (d, 3JC-P = 14.4 Hz, C=), 129.3 (CH-Ar), 128.23 (CH-Ar), 128.20 (CH-Ar), 128.0 (CH-
Ar), 127.9 (CH-Ar), 124.6 (CH-Ar), 124.5 (CH-Ar), 120.6 (d, 3JC-P = 4.0 Hz CH-Ar), 120.4 (d, 
3JC-P = 4.4 Hz CH-Ar), 117.5 (d, 2JC-P = 10.6 Hz, CH=), 116.9 (d, 2JC-P = 10.6 Hz, CH=), 101.2 
(C-5), 65.5 (CH2Ph), 66.4 (CH2Ph), 53.8 (d, 4JC-P = 2.2 Hz, CH2-N), 53.5 (d, 4JC-P = 2.4 Hz, 
CH2-N), 49.5 (CHCH3 L-Ala), 49.4 (CHCH3 L-Ala), 28.2 (d, 1JC-P = 129.7 Hz, CH2P), 28.0 (d, 
1JC-P = 130.1 Hz, CH2P), 19.7 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.2 Hz, CHCH3 
L-Ala), 13.2 (d, 4JC-P = 2.2 Hz, CH3, alkene), 13.1 (d, 4JC-P = 2.2 Hz, CH3, alkene). HPLC: 
Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to 100/0 in 
3Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳͶ.ͷ͸ min. 
HRMS (ESI): m/z [M+Na]+ calcd for C25H28N3O6P: 520.1608, found: 520.1608. 
 
4.1.3.11 (E)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-(isopropyloxy-L-Alanine)-phosphinyl-
2’-methyl-but-2’-enyl)uracil (E-10e) and (Z)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-
(isopropyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-enyl)uracil (Z-10e) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(5,6,7,8-tetrahydro-1-naphthyl)-(isopropyloxy-L-Alanine)-allylphosphonate 3e (200 
mg, 547.3 µmol) and N1-ʹ’-methylallyluracil (181 mg, 1.09 mmol) and Hoveyda-Grubbs 
2nd generation catalyst (15 mol%) in dry CH2Cl2 (10 ml). After evaporation, the crude 
was purified by Biotage Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient 
eluent system 2-propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture 
of the E and Z isomers. The two isomers were then separated by PrepHPLC (20 ml/min, 
isocratic eluting system CH3CN/H2O - 35/65, 30 minutes), to afford the title compound E 
as pale yellow foamy solid (31 mg, 11%). Rf = 0.23 (CH2Cl2/2-propanol - 95:5). 31P NMR 
(202 MHz, CD3OD) δP: 27.84, 27.00. 1H NMR (500 MHz, CD3OD) δH: 7.52-7.49 (m, 1H, 
H-6), 7.17-7.12 (m, 1H, ArH), 7.06-7.00 (m, 1H, ArH), 6.90-6.87 (m, 1H, ArH), 5.67 (d, J = 
7.9 Hz, 1H, H-5), 5.58-5.54 (m, 0.5H, CH=), 5.49-5.45 (m, 0.5H, CH=), 5.02-4.85 (m, 1H, 
CH(CH3)2), 4.35 (bs, 2H, CH2-N), 3.99-3.91 (m, 1H, CHCH3 L-Ala), 2.97-2.82 (m, 2H, CH2P), 
2.76 (bs, 2H, ArH), 2.69 (bs, 2H, ArH), 1.80-1.78 (m, 4H, ArH), 1.71 (d, J = 2.9 Hz 3H, CH3, 
alkene), 1.30 (d, J = 7.0 Hz, 1.5H, CHCH3 L-Ala), 1.25-1.24 (m, 4.5H, CHCH3 L-Ala, 
CH(CH3)2), 1.19 (d, J = 6.3 Hz, 3H, CH(CH3)2). 13C NMR (125 MHz, CD3OD) δC: 173.7 (d, 
3JC-P = 3.9 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.3 Hz, C=O, ester), 165.2 (C-4), 151.5 (C-2), 
151.4 (C-2), 148.8 (d, 2JC-P = 9.5 Hz, C-O, Ph), 148.6 (d, 2JC-P = 9.7 Hz, C-O, Ph), 145.35 (C-
6), 145.31 (C-6), 139.2 (C-Ar), 139.1 (C-Ar), 135.0 (d, 3JC-P = 14.5 Hz, C=), 134.6 (d, 3JC-P = 
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14.3 Hz, C=), 128.5 (d, 3JC-P = 5.4 Hz C-Ar), 128.3 (d, 3JC-P = 5.4 Hz C-Ar), 125.4 (CH-Ar), 
125.3 (CH-Ar), 125.15 (CH-Ar), 125.10 (CH-Ar), 117.6 (2JC-P = 11.0 Hz, CH=), 117.0 (2JC-P = 
10.9 Hz, CH=), 116.8 (d, 3JC-P = 3.3 Hz CH-Ar), 116.7 (d, 3JC-P = 3.3 Hz CH-Ar), 101.2 (C-5), 
101.1 (C-5), 68.67 (CH(CH3)2), 68.63 (CH(CH3)2), 53.8 (d, 4JC-P = 2.4 Hz, CH2-N), 53.5 (d, 
4JC-P = 2.4 Hz, CH2-N), 49.7 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 29.1 (CH2-Ar), 28.5 (d, 1JC-P 
= 129.9 Hz CH2P), 28.3 (d, 1JC-P = 130.9 Hz CH2P), 23.3 (CH2-Ar), 22.47 (CH2-Ar), 22.44 
(CH2-Ar), 22.42 (CH2-Ar), 20.6 (CH(CH3)2), 20.5 (CH(CH3)2), 20.4 (CH(CH3)2), 19.9 (d, 3JC-P 
= 5.0 Hz, CHCH3 L-Ala), 19.1 (d, 3JC-P = 5.5 Hz, CHCH3 L-Ala), 13.3 (d, 4JC-P = 2.3 Hz, CH3, 
alkene), 13.2 (d, 4JC-P = 2.0 Hz, CH3, alkene). HPLC: Reverse phase HPLC eluting with 
gradient method CH3CN/H2O from 10/90 to 100/0 in 30 minutes, ͳml/min, ɉ = ʹͷͶ nm 
and 263 nm, showed one peak with Rt 16.14 min. HRMS (ESI): m/z [M+Na]+ calcd for 
C25H34N3O6P: 526.2083, found: 526.2077. 
From PrepHPLC also the Z isomer Z-10e was isolated as pale yellow foamy solid (2.5 mg, 
1%). 31P NMR (202 MHz, CD3OD) δP: 29.39, 28.62. 1H NMR (500 MHz, CD3OD) δH: 7.50 
(d, J = 7.6 Hz, 1H, H-6), 7.10-7.00 (m, 1H, ArH), 6.95-6.88 (m, 1H, ArH), 6.80-6.75 (m, 1H, 
ArH), 5.54-5.38 (m 2H, CH=, H-5), 4.88-4.78 (m, 1H, CH(CH3)2), 4.38-4.29 (m, 2H, CH2-N), 
3.86-3.80 (m, 1H, CHCH3 L-Ala), 2.97-2.84 (m, 2H, CH2P), 2.66-2.58 (m, 4H, ArH), 1.71-
1.65 (m, 4H, ArH), 1.61-1.54 (m, 3H, CH3, alkene), 1.20-1.17 (m, 1.5H, CHCH3 L-Ala), 1.13-
1.07 (m, 7.5H, CHCH3 L-Ala, CH(CH3)2), 13C NMR (125 MHz, CD3OD) δC: 173.7 (d, 3JC-P = 
3.9 Hz, C=O, ester), 173.2 (d, 3JC-P = 4.3 Hz, C=O, ester), 165.2 (C-4), 151.5 (C-2), 151.4 (C-
2), 148.8 (d, 2JC-P = 9.5 Hz, C-O, Ph), 148.6 (d, 2JC-P = 9.7 Hz, C-O, Ph), 145.5 (C-6), 145.4 (C-
6), 139.2 (C-Ar), 135.0 (d, 3JC-P = 14.5 Hz, C=), 134.6 (d, 3JC-P = 14.3 Hz, C=), 128.5 (d, 3JC-P = 
5.4 Hz C-Ar), 128.3 (d, 3JC-P = 5.4 Hz C-Ar), 125.3 (CH-Ar), 125.2 (CH-Ar), 125.1 (CH-Ar), 
125.0 (CH-Ar), 119.5 (2JC-P = 10.1 Hz, CH=), 119.4 (2JC-P = 10.8 Hz, CH=), 117.1 (d, 3JC-P = 
3.3 Hz CH-Ar), 116.8 (d, 3JC-P = 3.3 Hz CH-Ar), 101.1 (C-5), 101.0 (C-5), 68.6 (CH(CH3)2), 
49.7 (CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 47.0 (CH2-N), 29.1 (CH2-Ar), 28.2 (d, 1JC-P = 128.2 
Hz CH2P), 28.0 (d, 1JC-P = 130.5 Hz CH2P), 23.4 (CH2-Ar), 23.3 (CH2-Ar), 22.47 (CH2-Ar), 
22.43 (CH2-Ar), 20.57 (CH(CH3)2), 20.53 (CH(CH3)2), 20.4 (CH(CH3)2), 19.7 (d, 3JC-P = 4.7 
Hz, CHCH3 L-Ala), 19.0 (d, 3JC-P = 5.4 Hz, CHCH3 L-Ala), 13.3 (d, 4JC-P = 2.7 Hz, CH3, 
alkene).HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 
10/90 to 100/0 in 30 minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with 
Rt 16.82 min. 
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4.1.3.12 (E)-N1-(4’-O-(5,6,7,8-tetrahydro-1-naphthyl)-(benzyloxy-L-Alanine)-phosphinyl-2’-
methyl-but-2’-enyl)uracil (E-10f) 
Prepared according to the standard procedure C for the synthesis of ANP ProTide using 
O-(5,6,7,8-tetrahydro-1-naphthyl)-(benzyloxy-L-Alanine)-allylphosphonate 3f (200 mg, 
483.7 µmol) and N1-ʹ’-methylallyluracil (160 mg, 967.4 µmol) and Hoveyda-Grubbs 2nd 
generation catalyst (15 mol%) in dry CH2Cl2 (8 ml). After evaporation, the crude was 
purified by Biotage Isolera One (25 g SNAP cartridge ULTRA, 75 ml/min, gradient eluent 
system 2-propanol/CH2Cl2 1% 1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E 
and Z isomers. The two isomers were then separated by PrepHPLC (20 ml/min, isocratic 
eluting system CH3CN/H2O - 40/60, 30 minutes), to afford the title compound as pale 
yellow foamy solid (14 mg, 5%). Rf = 0.25 (CH2Cl2/2-propanol - 95:5). 31P NMR (202 
MHz, CD3OD) δP: 29.33, 28.46. 1H NMR (500 MHz, CD3OD) δH: 7.34 (d, J = 7.8 Hz, 1H, H-
6), 7.26-7.18 (m, 5H, ArH), 7.03-6.99 (m, 1H, ArH), 6.93-6.83 (m, 1H, ArH), 6.77-6.73 (m, 
1H, ArH), 5.54 (d, J = 7.8 Hz, 0.6H, H-5), 5.53 (d, J = 7.9 Hz, 0.4H, H-5), 5.39-5.29 (m, 1H, 
CH=), 5.04, 5.01 (ABq, JAB = 12.2 Hz, 1H, CH2Ph), 4.95, 4.94 (ABq, JAB = 12.2 Hz, 1H, 
CH2Ph), 4.19-4.17 (m, 2H, CH2-N), 3.97-3.88 (m, 1H, CHCH3 L-Ala), 2.78-2.765 (m, 2H, 
CH2P), 2.63 (bs, 2H, ArH), 2.56 (bs, 2H, ArH), 1.67-1.62 (m, 4H, ArH), 1.54 (d, J = 3.8 Hz 
1.8H, CH3, alkene), 1.52 (d, J = 3.9 Hz 1.2H, CH3, alkene), 1.20 (d, J = 6.9 Hz, 1.8H, CHCH3 
L-Ala), 1.14 (d, J = 7.0 Hz, 1.2H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 173.9 (d, 
3JC-P = 4.0 Hz, C=O, ester), 173.4 (d, 3JC-P = 4.0 Hz, C=O, ester), 165.2 (C-4), 151.5 (C-2), 
151.4 (C-2), 148.8 (d, 2JC-P = 9.1 Hz, C-O, Ph), 148.7 (d, 2JC-P = 9.7 Hz, C-O, Ph), 145.3 (C-6), 
145.2 (C-6), 139.2 (C-Ar), 139.1 (C-Ar), 135.9 (C-Ar), 135.8 (C-Ar), 134.9 (d, 3JC-P = 14.7 
Hz, C=), 134.7 (d, 3JC-P = 14.7 Hz, C=), 128.4 (d, 3JC-P = 4.7 Hz C-Ar), 128.3 (d, 3JC-P = 4.7 Hz 
C-Ar), 128.2 (CH-Ar), 128.1 (CH-Ar), 127.9 (CH-Ar), 127.8 (CH-Ar), 125.4 (CH-Ar), 125.3 
(CH-Ar), 125.15 (CH-Ar), 125.08 (CH-Ar), 117.5 (2JC-P = 10.9 Hz, CH=), 117.0 (2JC-P = 10.9 
Hz, CH=), 116.8 (d, 3JC-P = 3.2 Hz CH-Ar), 116.6 (d, 3JC-P = 3.2 Hz CH-Ar), 101.17 (C-5), 66.5 
(CH2Ph), 66.4 (CH2Ph), 53.8 (d, 4JC-P = 2.5 Hz, CH2-N), 53.5 (d, 4JC-P = 2.5 Hz, CH2-N), 49.6 
(CHCH3 L-Ala), 49.5 (CHCH3 L-Ala), 29.1 (CH2-Ar), 28.4 (d, 1JC-P = 130.0 Hz CH2P), 28.2 (d, 
1JC-P = 130.8 Hz CH2P), 23.3 (CH2-Ar), 22.44 (CH2-Ar), 22.42 (CH2-Ar), 22.39 (CH2-Ar), 19.7 
(d, 3JC-P = 5.4 Hz, CHCH3 L-Ala), 19.0 (d, 3JC-P = 5.6 Hz, CHCH3 L-Ala), 13.2 (d, 4JC-P = 2.3 Hz, 
CH3, alkene), 13.1 (d, 4JC-P = 2.4 Hz, CH3, alkene). HPLC: Reverse phase HPLC eluting with 
gradient method CH3CN/H2O from ͳͲ/9Ͳ to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm 
and 263 nm, showed one peak with Rt 17.66 min. HRMS (ESI): m/z [M+Na]+ calcd for 
C29H34N3O6P: 574.2083, found: 574.2077. 
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4.1.4 Bis(benzyloxy-L-Alanine)-allylphosphonate (11) 
In a round bottom flask, under an argon atmosphere, 2,6-Lutidine (1.55 ml. 13.22 mmol) 
and TMSBr, (2.20 ml, 16.65 mmol) were added to a solution of dimethyl 
allylphosphonate (500 mg, 3.33 mmol), in anhydrous acetonitrile (25 ml). The mixture 
was stirred 16 h at room temperature and then the volatiles evaporated without any 
contact with air. Then the flask was charged with dry aminoacid ester hydrochloride 
(3.6 g, 16.65 mmol), dry triethylamine (6.9 ml, 49.96 mmol) and dry pyridine (10 ml) and heated to ͷͲ˚C to obtain a homogenous solution. To this mixture was then added a 
solution of Aldrithiol-2 (4.40 g, 19.98 mmol) and triphenylphosphine (5.24 g, 19.98 
mmol) in dry pyridine (10 ml) under argon atmosphere. The resulting mixture was stirred at ͷͲ˚C for ͳ͸ h. After evaporating all the volatiles, the residue was purified by 
Biotage Isolera One (100 g SNAP cartridge ULTRA, 100 ml/min, gradient eluent system 
EtOAc/Hexane 10% 1CV, 10-100% 12CV, 100% 2CV and 50 g SNAP cartridge ULTRA, 
100 ml/min, gradient eluent system MeOH/EtOAc 0% 1CV, 0-20% 15CV, 20% 3CV), to 
afford the title compound as a yellow oil (770 mg, 52%). Rf = 0.44 (EtOAc/MeOH - 98:2). 
31P NMR (202 MHz, CD3OD) δP: 27.47. 1H NMR (500 MHz, CD3OD) δH: 7.39-7.29 (m, 
10H, ArH), 5.88-5.79 (m, 1H, CH=), 5.19-5.09 (m, 6H, CH2=, 2xCH2Ph), 4.07-4.01 (m, 2H, 
2xCHCH3 L-Ala), 21.36 (dd, JG = 19.5 Hz, J = 7.2 Hz, 2H, CH2P), 1.41 (d, J = 7.0 Hz, 3H, 
CHCH3 L-Ala), 1.31 (d, J = 7.2 Hz, 3H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 
174.28 (d, 3JC-P = 4.3 Hz, C=O, ester), 174.23 (d, 3JC-P = 4.3 Hz, C=O, ester), 135.95 (C-Ar), 
135.91 (C-Ar), 128.5 (2JC-P = 10.9 Hz, CH=), 128.36 (CH-Ar), 128.33 (CH-Ar), 128.1 (CH-
Ar), 128.0 (CH-Ar), 119.0 (d, 3JC-P = 13.0 Hz CH2=), 66.6 (CH2Ph), 66.5 (CH2Ph), 48.9 
(CHCH3 L-Ala), 48.5 (CHCH3 L-Ala), 34.7 (d, 1JC-P = 111.4 Hz CH2P), 19.9 (d, 3JC-P = 5.4 Hz, 
CHCH3 L-Ala), 19.8 (d, 3JC-P = 4.3 Hz, CHCH3 L-Ala). 
 
4.1.5 (E)-N1-(bis(benzyloxy-L-Alanine)-phosphinyl-2’-methyl-but-2’-enyl)uracil (12) 
Prepared according to the standard procedure C using bis(benzyloxy-L-Alanine)-
allylphosphonate 11 (200 mg, 854.9 µmol) and N1-ʹ’-methylallyluracil (150 mg, 1.71 
mmol) and Hoveyda-Grubbs 2nd generation catalyst (15 mol%) in dry CH2Cl2 (10 ml). 
Volatiles were then evaporated and the residue was purified by Biotage Isolera One (25 
g SNAP cartridge ULTRA, 75 ml/min, gradient eluent system 2-propanol/CH2Cl2 1% 
1CV, 1-10% 12CV, 10% 2CV), to afford a mixture of the E and Z isomers. The two 
isomers were then separated by Preparative HPLC (20 ml/min, gradient eluting system 
CH3CN/H2O from 5/95 to 100/0, 30 minutes), to afford the title compound as pale 
yellow foamy solid (5 mg, 2%). Rf = 0.30 (CH2Cl2/2-propanol - 95:5). 31P NMR (202 
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MHz, CD3OD) δP: 27.88. 1H NMR (500 MHz, CD3OD) δH: 7.36 (d, J = 7.9 Hz, 1H, H-6), 
7.28-7.17 (m, 10H, ArH), 5.56 (d, J = 7.9 Hz, 1H, H-5), 5.32-5.28 (m, 1H, CH=), 5.06, 4.99 
(m, 4H, 2xCH2Ph), 4.14 (s, 2H, CH2-N), 3.91-3.84 (m, 2H, 2xCHCH3 L-Ala), 2.55-2.41 (m, 
2H, CH2P), 1.50 (d, J = 3.1 Hz, 3H, CH3, alkene), 1.26 (d, J = 7.1 Hz, 3H, CHCH3 L-Ala), 1.18 
(d, J = 7.1 Hz, 3H, CHCH3 L-Ala). 13C NMR (125 MHz, CD3OD) δC: 174.3 (d, 3JC-P = 4.6 Hz, 
C=O, ester), 174.1 (d, 3JC-P = 3.7 Hz, C=O, ester), 165.2 (C-4), 151.5 (C-2), 145.2 (C-6), 
135.95 (C-Ar), 135.91 (C-Ar), 133.9 (d, 3JC-P = 13.8 Hz, C=), 128.22 (CH-Ar), 128.21 (CH-
Ar), 128.04 (CH-Ar), 128.01 (CH-Ar), 127.98 (CH-Ar), 127.96 (CH-Ar), 118.7 (d, 2JC-P = 9.7 
Hz, CH=), 101.2 (C-5), 66.58 (CH2Ph), 66.53 (CH2Ph), 53.7 (d, 4JC-P = 2.4 Hz, CH2-N), 48.8 
(CHCH3 L-Ala), 48.5 (CHCH3 L-Ala), 29.0 (d, 1JC-P = 112.5 Hz, CH2P), 19.8 (d, 3JC-P = 5.4 Hz, 
CHCH3 L-Ala), 19.6 (d, 3JC-P = 4.8 Hz, CHCH3 L-Ala), 13.1 (d, 4JC-P = 2.0 Hz, CH3, alkene). 
HPLC: Reverse phase HPLC eluting with gradient method CH3CN/H2O from 10/90 to ͳͲͲ/Ͳ in ͵Ͳ minutes, ͳml/min, ɉ = ʹͷͶ nm and ʹ͸͵ nm, showed one peak with Rt ͳͷ.͹9 
min. HRMS (ESI): m/z [M+Na]+ calcd for C29H35N4O7P: 605.2141, found: 605.2136. 
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